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A B S T R A C T
Excitotoxicity, the speciﬁc type of neurotoxicity mediated by glutamate, may be the missing link between
ischemia and neuronal death, and intervening the mechanistic steps that lead to excitotoxicity can
prevent stroke damage. Interest in excitotoxicity began ﬁfty years ago when monosodium glutamate was
found to be neurotoxic. Evidence soon demonstrated that glutamate is not only the primary excitatory
neurotransmitter in the adult brain, but also a critical transmitter for signaling neurons to degenerate
following stroke. The ﬁnding led to a number of clinical trials that tested inhibitors of excitotoxicity in
stroke patients. Glutamate exerts its function in large by activating the calcium-permeable ionotropic
NMDA receptor (NMDAR), and different subpopulations of the NMDAR may generate different functional
outputs, depending on the signaling proteins directly bound or indirectly coupled to its large cytoplasmic
tail. Synaptic activity activates the GluN2A subunit-containing NMDAR, leading to activation of the pro-
survival signaling proteins Akt, ERK, and CREB. During a brief episode of ischemia, the extracellular
glutamate concentration rises abruptly, and stimulation of the GluN2B-containing NMDAR in the
extrasynaptic sites triggers excitotoxic neuronal death via PTEN, cdk5, and DAPK1, which are directly
bound to the NMDAR, nNOS, which is indirectly coupled to the NMDAR via PSD95, and calpain, p25, STEP,
p38, JNK, and SREBP1, which are further downstream. This review aims to provide a comprehensive
summary of the literature on excitotoxicity and our perspectives on how the new generation of
excitotoxicity inhibitors may succeed despite the failure of the previous generation of drugs.
 2013 The Authors. Published by Elsevier Ltd. 
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In the past several decades, excitotoxicity, a type of neurotox-
icity mediated by glutamate, has been at the center stage of stroke
research. Glutamate is the principle neurotransmitter in the adult
central nervous system. In addition to being required for the rapid
synaptic transmission that is critical for neuron-to-neuron
communication, glutamate plays important roles in neuronal
growth and axon guidance, brain development and maturation,
and synaptic plasticity in health and disease. Among the ionotropic
and metabotropic glutamate receptors in the adult central nervous
system, the N-methyl-D-aspartate (NMDA) type of glutamate
receptor (the NMDAR) acts as a hub, by detecting and processing
extracellular glutamate signals into diverse intracellular signaling
outputs. With the emergence of cellular and molecular biology,
scientists are unraveling the mechanisms by which glutamate-
mediated activation of the NMDAR in health and disease transmits
so many different functional outputs, at both the microscopic
neuron level and the macroscopic behavior level. These mecha-
nisms have important implications for research concerning
excitotoxicity and its role in ischemic neuronal death. The
identiﬁcation of distinct intracellular pathways linking NMDAR
activation to neuronal death allows scientists to develop novel
treatments that target speciﬁc death signaling pathways without
affecting all the signaling pathways downstream of the receptor.
This increased speciﬁcity not only translates into reduced sideeffects but also increases the therapeutic window in which the
drug can be efﬁcaciously administered.
2. Stroke and the NMDAR
Compared to other tissues and organs in the body, the brain is
particularly prone to ischemic damage. Unlike the immediate
ischemic damage that is observed in other tissues, a transient
period of cerebral ischemia (approximately 10 min) can produce
profound neuronal damage that only becomes evident 3d post-
ictus and continues progressively for months. As relief of vascular
occlusion is the primary method by which tissue ischemia is
treated in the clinic, the propensity for ischemic damage to occur
regardless of the recovery of blood ﬂow highlights the need for an
alternative method for treating cerebral ischemia. Importantly, the
delayed and progressive nature of neuronal damage following
cerebral ischemia points to a wide time window for therapeutic
intervention and emphasizes the importance of understanding the
nature of ischemic neuronal death. An improved understanding of
the processes that translate cerebral ischemia into neuronal
damage would highlight new therapeutic targets for stopping the
seemingly inevitable progression from ischemia to neuronal death.
One explanation for the peculiar susceptibility of the brain to
ischemic damage is that brain tissue contains high levels of the
neurotoxic excitatory neurotransmitter glutamate, and many
neurons in the brain contain receptors that actively respond to
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massive release of glutamate, which stimulates the NMDAR and
induces calcium inﬂux through these ionotropic receptors, the
calcium-dependent activation of death-signaling proteins that are
immediately downstream of the receptors triggers a plethora of
signaling cascades that work synergistically to induce neuronal
death.
2.1. Glutamate and excitotoxicity
Neuroscientists have made progress in understanding the role
of the NMDAR in glutamate-mediated excitotoxic damage.
Initially, interest in this topic was based on the observation that
monosodium glutamate, a popular food additive in Chinese
restaurants, is neurotoxic to the inner layer of the mouse retina
(Lucas and Newhouse, 1957). This observation was soon followed
by the ﬁnding that glutamate is excitatory: it can depolarize
neurons, causing them to ﬁre action potentials (Curtis et al., 1959).
It has subsequently been shown that the neurotoxic effect of
monosodium glutamate is not limited to the mouse retina but
extends to the peripheral and central neurons in mice, rats, rabbits,
and rhesus monkeys (Burde et al., 1971; Freedman and Potts, 1962,
1963; Olney, 1969a,b; Olney and Sharpe, 1969). In addition, this
effect can be mimicked by other amino acids that are excitatory to
neurons (Olney, 1971; Olney and Ho, 1970; Olney et al., 1971,
1974) but not by non-excitatory amino acids (Olney and Ho, 1970;
Olney et al., 1971). Importantly, this neuronal damage can be
induced following oral intake of relatively low doses of mono-
sodium glutamate (Burde et al., 1971; Olney and Ho, 1970), which
raises concerns about the common use of this additive in diets.
Because glutamate is excitatory and other related excitatory amino
acids are also neurotoxic, these amino acids are collectively called
excitotoxins, and their associated neuronal damage is called
excitotoxicity.
2.1.1. Ionic mechanism of excitotoxicity
In investigations concerning the mechanism of excitotoxicity,
several hypotheses have been proposed that suggest an ionic basis
for neurotoxicity. The concept of excitotoxicity originates from the
idea that because neurotoxic glutamate analogs are structurally
similar, these molecules are likely to elicit neurotoxicity by a
common mechanism (Olney et al., 1971, 1974). The bold
hypothesis that excitotoxicity is ‘‘in essence, an exaggeration of
the excitatory effect’’ (Olney et al., 1974) follows from this theory.
This hypothesis is supported by the ﬁndings that glutamate
analogs that are excitatory are also neurotoxic and that the
neurotoxic potency of these analogs correlates with their potency
in inducing neuronal excitation (Olney et al., 1971). In addition,
glutamate analogs that are not excitatory are not neurotoxic
(Olney et al., 1971). Further, glutamate-mediated neuronal
excitation is expected to occur in postsynaptic locations (soma
and dendrites), and these locations are also the origin of rapid
neuronal swelling, a pathological feature that is thought to underlie
excitotoxicity (Olney et al., 1971, 1974). Finally, drugs that
antagonize glutamate-mediated neuronal excitation also prevent
the associated neurotoxicity. In contrast to the concept of
excitotoxicity, which suggests that the sodium cation is a key
molecule in neurotoxicity, many cytotoxic processes in neuronal
and non-neuronal tissues, such as the heart, the muscles, and the
liver, require the divalent calcium cation (Berdichevsky et al., 1983;
Coyle, 1983). The extension of this calcium hypothesis to
excitotoxicity is further corroborated by experimental evidence
demonstrating that glutamate and other excitatory amino acids also
increase calcium inﬂux into neurons (Berdichevsky et al., 1983;
Jancso et al., 1984) and that non-neurotoxic amino acids do not
increase calcium inﬂux (Berdichevsky et al., 1983). Importantly,among several glutamate analogs, N-methyl-DL-aspartate is the
most potent in increasing calcium inﬂux and is also the most potent
in inducing neurotoxicity. This ﬁnding led to the initial hypothesis
that the glutamate receptor subtype that is activated by N-methyl-
DL-aspartate (now known as the NMDAR) underlies glutamate-
mediated excitotoxicity (Berdichevsky et al., 1983).
Because it is virtually impossible to study the ionic mechanism
of glutamate neurotoxicity in vivo, most studies are performed in
primary neurons in vitro. Thus, controversies can arise from
differences in experimental technique and differences in the
endpoint used to deﬁne neuronal damage. The aforementioned
rapid neuronal swelling, which occurs immediately upon treat-
ment with glutamate, is completely abolished by the removal of
sodium ions (Olney et al., 1986; Rothman, 1985), but it is not
affected by the removal of calcium ions (Olney et al., 1986; Price
et al., 1985; Rothman, 1985). In addition, in the absence of
glutamate or other excitatory amino acids, excitation of neurons by
increasing the concentration of potassium ions in the culture
medium also induces neuronal swelling (Olney et al., 1986;
Rothman, 1985). Together, these data support the excitotoxicity
hypothesis that proposes that excitotoxicity is an exaggeration of
neuronal excitation mediated by sodium ions and that any source
of excitation (even those that are not mediated by excitatory amino
acids) is potentially harmful. In contrast to the neuronal swelling
that occurs immediately upon glutamate treatment, the delayed
neuronal death that is observed 24 h after glutamate treatment is
abolished by the removal of calcium and potentiated by increased
calcium levels (Choi, 1985). In addition, the removal of sodium ions
from the culture medium prior to glutamate treatment prevents
neuronal swelling but does not affect the neuronal death that
occurs 24 h later (Choi, 1987). More importantly, while the
removal of calcium exacerbates acute glutamate-induced neuronal
swelling, this change prevents the delayed neuronal death that
typically occurs 24 h later (Choi, 1987). In addition, the rapid
neuronal swelling and related morphological and pathological
features that are caused by glutamate challenge eventually recover
over time (Choi, 1987). This ﬁnding highlighted the critical role of
calcium ions in glutamate-mediated neurotoxicity. At the same
time, emerging experimental evidence began to suggest that
NMDARs, the most calcium-permeable ionotropic glutamate
receptors, are responsible for the ischemic neuronal damage that
follows stroke.
2.1.2. Calcium homeostasis and distinct pathways toward death and
survival
The calcium ion is one of the most important signaling
molecules in cell biology, and tight regulation of intracellular
calcium level by means of sequestration and extrusion is crucial for
cellular function. Given the essential role of calcium in glutamate-
mediated injury (see Section 2.1.1), dysfunction of calcium
homeostatic machineries are expected to exacerbate calcium
overload and contribute to excitotoxicity. Moreover, the initial
calcium inﬂux following excitotoxic glutamate stimulation is
known to trigger a secondary intracellular calcium overload, and
this secondary response strongly correlates with neuronal death
(Randall and Thayer, 1992; Tymianski et al., 1993a). One important
regulator of intracellular calcium level is the plasma membrane
sodium-calcium exchanger (NCX), which extrudes calcium using
driving force from sodium inﬂux. Following glutamate stimulation,
calcium extrusion by NCX partially recovers intracellular calcium
concentration back to physiological level (White and Reynolds,
1995). More recently, it has been shown that NMDAR-mediated
dysfunction of NCX explains the subsequent calcium overload that
occurs following an excitotoxic stimulus, and that replacement of
the defective NCX with a non-compromised isoform prevents
excitotoxic neuronal death (Bano et al., 2005) (see Section 4.3). In
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direction during the early phase of glutamate stimulation (Hoyt
et al., 1998). While this contributes to early glutamate-mediated
calcium loading, it does not contribute to the calcium overload and
neuronal death upon prolonged glutamate exposure (Hoyt et al.,
1998). Another major player in cellular calcium homeostasis is
mitochondria. Mitochondria can recover intracellular calcium
concentration by (1) itself taking up a huge amount of calcium
(White and Reynolds, 1996, 1997), and by (2) facilitating ATP-
dependent calcium extrusion (Budd and Nicholls, 1996a,b).
Importantly, inhibition of both mitochondria and NCX completely
prevents recovery of calcium level following glutamate stimula-
tion (White and Reynolds, 1995). Upon excitotoxic glutamate
stimulation, the mitochondrial uptake of calcium in turn results in
the production of reactive oxygen species (ROS) (Castilho et al.,
1999; Reynolds and Hastings, 1995), opening of the permeability
transition pore that results in mitochondrial depolarization
(Abramov and Duchen, 2008; Vergun et al., 1999; White and
Reynolds, 1996), induction of calcium deregulation (Castilho et al.,
1998, 1999; Keelan et al., 1999; Ward et al., 2000), and induction of
neuronal death (Stout et al., 1998). In addition, the mitochondrial
NCX (mNCX) mediates extrusion of calcium from mitochondria
into the cytoplasm, and this also partially contributes to the
delayed cytoplasmic calcium loading during excitotoxicity (White
and Reynolds, 1996, 1997). Notably, the uncoupling proteins
(UCPs) 2 and 3 have recently been identiﬁed to be the
mitochondrial calcium uniporter (MCU) (Trenker et al., 2007)
(but see also Brookes et al., 2008). Genetic knockdown of MCU
prevents mitochondrial calcium uptake in response to glutamate
and other stimuli (Brookes et al., 2008; Qiu et al., 2013), and
prevents NMDAR-mediated mitochondrial depolarization and
excitotoxic neuronal death (Qiu et al., 2013). In contrast, MCU
overexpression promotes NMDAR-mediated mitochondrial calci-
um uptake, and thereby exacerbates mitochondrial depolarization
and neuronal injury (Qiu et al., 2013).
The spatial and temporal regulation of intracellular calcium ion
distribution entails that calcium input from different sources and
under different conditions can have very different consequences.
While the essential role of the calcium ion in excitotoxicity
explains the prominent role of the NMDAR over less calcium-
permeable types of glutamate receptors in this phenomenon, it
does not explain why calcium input from the NMDAR is neurotoxic
while calcium input from other sources can be neuroprotective. For
example, stimulation of voltage-gated calcium channels promotes
the survival of cultured neurons in vitro (Balazs et al., 1990; Gallo
et al., 1987; Ghosh et al., 1994) and protects them from neuronal
death mediated by the NMDAR (Balazs et al., 1990) or by nerve
growth factor starvation (Koike et al., 1989). In vivo studies in the
mouse brain demonstrated that reducing calcium loading by
inhibiting voltage-gated calcium channels exacerbates, rather than
attenuates, excitotoxicity induced by glutamate or N-methyl-D-
aspartate (Price et al., 1985). The observed differential effects of
different calcium sources could not be due to differences in
calcium loading, because calcium loading induced by glutamate
via NMDARs is more neurotoxic than equivalent calcium loading
induced by depolarization via voltage-gated calcium channels
(Tymianski et al., 1993b). The differential effects on neuronal death
and survival that result from these different calcium inputs can be
partially explained by their differential effects on gene expression
(Bading et al., 1993; Ghosh et al., 1994), such as their differential
effect on the expression of brain-derived neurotrophic factor
(BDNF) (Ghosh et al., 1994). Thus, although calcium overload is
almost always detrimental and has been shown to be tightly
associated with neuronal death (Randall and Thayer, 1992;
Tymianski et al., 1993a), transient calcium inﬂux can have distinct
functions, including neuroprotective and neurodegenerativeeffects, depending on the source of the calcium (Bading et al.,
1993; Ghosh et al., 1994; Tymianski et al., 1993b) or the location of
the calcium transient (Hardingham et al., 1997). The pivotal role of
the NMDAR as a source of death-signaling calcium led to the
prominent theory that some calcium-dependent death-signaling
proteins must be closely associated with, if not physically bound
to, the NMDAR (Tymianski et al., 1993b). Today, mounting
evidence has indicated that the C-terminal domain of the NMDAR
directly binds to many death-signaling proteins.
2.2. Dual role of the NMDAR in death and survival
The NMDAR is not always excitotoxic. This receptor is known to
have dual-effects; it promotes neuronal death or survival in
primary neuronal cultures in vitro and in the rat brain in vivo,
depending on the level of receptor activity. For example, NMDAR
stimulation with a low dose of N-methyl-D-aspartate promotes
neuronal survival in granule cell cultures (Balazs et al., 1988a,b,
1989; Didier et al., 1989; Yan et al., 1994), and under the same
culture conditions, NMDAR stimulation with a high dose of N-
methyl-D-aspartate induces neuronal death (Yan et al., 1994). In
comparison, NMDAR inhibition by a low dose of the antagonist 2-
amino 5-phosphonovaleric acid promotes neuronal survival in
spinal cord cultures, but a high dose of the same antagonist induces
neuronal death (Brenneman et al., 1990a,b). Consistent with these
in vitro data, pharmacological inhibition or genetic deletion of the
NMDAR yields widespread neuropathy and neuronal death in the
rat brain in vivo (Adams et al., 2004; Gould et al., 1994; Hansen
et al., 2004; Ikonomidou et al., 1999) during a developmental
period in which the rat brain is most prone to NMDAR-mediated
excitotoxic neuronal death (Ikonomidou et al., 1989b). These
ﬁndings suggested that the NMDAR could promote either neuronal
death or survival under the same culture conditions in vitro or
during the same stage of brain development in vivo, depending
only on the level of NMDAR activity. This premature speculation,
which is known as the set-point hypothesis, stipulates that there is
an optimal level of intracellular calcium ions, such that too much or
too little calcium input from the NMDAR or other sources can
induce neuronal death (Choi, 1995; Franklin and Johnson, 1992;
Koike et al., 1989). However, this hypothesis does not explain why
the age at which the rat brain is most susceptible to NMDAR-
inhibition is also the age at which the rat brain is most vulnerable
to NMDAR-stimulation (Ikonomidou et al., 1989b, 1999). In light of
the differential roles of distinct sources of calcium input on
neuronal death and survival, emerging evidence points to distinct
NMDAR subpopulations that differentially promote neuronal
death and survival. Importantly, the disruptive effect of a
neuropeptide on the excitotoxic but not the survival-promoting
effect of the NMDAR suggests that these effects are mediated by
distinct downstream mechanisms (Brenneman et al., 1990b).
2.2.1. Neuronal survival mediated by synaptic NMDAR
Neuronal survival is activity-dependent. The potentiation of
neuronal activity by depolarization or NMDAR stimulation can
enhance neuronal survival in cultures in vitro (Balazs et al.,
1988a,b, 1989; Didier et al., 1989; Gallo et al., 1987), and the
potentiation of neuronal activity by means of environmental
enrichment induces a 45% decline in spontaneous neuronal death
in vivo (Young et al., 1999). In addition, environmental enrichment
protects the brain against excitotoxic injury (Young et al., 1999).
Given the speciﬁc localization of many synaptic and extrasynaptic
proteins, it is possible that synaptic and extrasynaptic NMDARs can
be functionally coupled to different downstream signaling
proteins, conferring differential effects on neurons. The propensity
for synaptic activity to promote neuronal survival lends support to
the hypothesis that synaptic NMDAR can promote neuronal
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there is too much glutamate in the brain, such as during cerebral
ischemia (Benveniste et al., 1984), can induce neuronal death.
Although early attempts to differentiate the distinct capacities of
synaptic and extrasynaptic NMDARs to induce excitotoxicity were
unsuccessful (Sattler et al., 2000), subsequent work from several
groups demonstrated that synaptic and extrasynaptic NMDARs
have differential and sometimes opposing functions in neurons
(Hardingham et al., 2002; Ivanov et al., 2006; Lu et al., 2001). These
opposing functions include the induction of neuroprotective and
neurodegenerative effects (Hardingham et al., 2002). In particular,
synaptic NMDAR conveys the synaptic activity-driven activation of
the survival-signaling protein extracellular signal-regulated kinase
(ERK) (Chandler et al., 2001; Hardingham et al., 2001a; Leveille
et al., 2008) and triggers an increase in nuclear calcium via release
from intracellular stores, leading to the activation of the
transcription factor CREB (Hardingham et al., 2001b) and the
production of the survival-promoting protein BDNF (Hardingham
et al., 2002). In contrast, global or extrasynaptic NMDAR
stimulation decreases ERK activation (Chandler et al., 2001;
Ivanov et al., 2006; Leveille et al., 2008), and extrasynaptic NMDAR
stimulation decreases CREB activation and BDNF production
(Hardingham et al., 2002). Most importantly, synaptic NMDAR
stimulation protects neurons against staurosporine-induced and
starvation-induced neuronal death (Hardingham et al., 2002;
Papadia et al., 2005; Soriano et al., 2006; Zhang et al., 2007), while
global stimulation of the NMDAR induces neuronal death (Gouix
et al., 2009; Hardingham et al., 2002; Zhang et al., 2007). Consistent
with the extrasynaptic localization of the GluN2B-containing
NMDAR, selective inhibition of this NMDAR subtype protects
neurons against global NMDAR stimulation (Hardingham et al.,
2002). The ﬁnding that synaptic NMDAR promotes neuronal
survival has important physiological implications (Fig. 1A and B): it
provides a mechanistic explanation for the observation that
synaptic activity mediates neuronal survival and provides
neuroprotection against central distress (Young et al., 1999) and
for the observation that NMDAR antagonism can be detrimental to
the developing and adult brain (Gould et al., 1994; Ikonomidou
et al., 1999) and hinder recovery of the brain from injury
(Ikonomidou et al., 2000). In addition, the death-signaling property
of extrasynaptic NMDAR provides an explanation for the ﬁnding
that glutamate spillover under pathological conditions, such as
cerebral ischemia, induces neuronal death.
Although synaptic NMDAR preferentially promotes neuronal
survival (and extrasynaptic NMDAR preferentially promotes
neuronal death), synaptic NMDAR is not exclusively pro-survival.
First, the synaptic release of glutamate induces hypoxic neuronal
death in primary hippocampal neurons (Rothman, 1983, 1984),
and the inhibition of synaptic NMDAR protects neurons against
hypoxic neuronal death (Wroge et al., 2012; Zhou et al., 2013).
Likewise, a substrate inhibitor for the glutamate transporter
induces prominent excitotoxicity in glial-lacking neuronal cultures
at a dose that stimulates almost exclusively synaptic NMDAR
(Gouix et al., 2009). Second, relieving synaptic NMDARs (allowing
their relocation to extrasynaptic sites) failed to exacerbate
NMDAR-mediated neuronal death (Sattler et al., 2000). In addition,
postsynaptic density protein 95 (PSD95), the most well character-
ized NMDAR-conjugating death-signaling protein (see Section 4.2),
is predominantly synaptic rather than extrasynaptic (Butko et al.,
2012; Cho et al., 1992; Kornau et al., 1995), although exceptions
have been observed (Petralia et al., 2010). In primary cortical
neurons, knocking down PSD95 expression in the synapse prevents
NMDAR-mediated excitotoxicity (Sattler et al., 1999). Third, in the
presence of NVP-AAM007, an antagonist that preferentially
inhibits the GluN2A-containing NMDAR, the direct stimulation
of synaptic (presumably GluN2A-lacking) NMDAR in primarycortical neurons can induce neuronal death (Liu et al., 2007). Thus,
some synaptic NMDARs can induce neuronal death. In addition,
selective inhibition of synaptic NMDAR attenuates the excitotoxi-
city that is induced by global NMDAR stimulation in primary
hippocampal neurons, further supporting the ﬁnding that synaptic
NMDAR also contributes to excitotoxicity (Wroge et al., 2012).
Finally, it is important to note that most of the studies on the
distinct contributions made by synaptic and extrasynaptic NMDAR
to neuronal death and survival took advantage of the pharmaco-
logical properties of MK-801, which is a high-afﬁnity uncompeti-
tive antagonist used to pre-block synaptic NMDAR for a prolonged
period of time, and memantine (Milnerwood et al., 2010; Okamoto
et al., 2009), which is a low-afﬁnity uncompetitive antagonist
thought to act speciﬁcally on extrasynaptic NMDARs (Leveille
et al., 2008; Okamoto et al., 2009; Xia et al., 2010). However, recent
work has questioned the duration of the synaptic block by MK-801
under different experimental paradigms (McKay et al., 2013) and
the speciﬁcity of memantine at the doses used in previous studies
(Wroge et al., 2012; Zhou et al., 2013). Several questions remain
unanswered and warrant future research. How does the NMDAR
exert location-speciﬁc output? Is the location of synaptic NMDAR
mandatory for its promotion of neuronal survival? Does extra-
synaptic NMDAR induce neuronal death as a result of its location?
In light of the respective roles of synaptic and extrasynaptic
NMDARs in neuronal survival and death, one important avenue of
future research is to determine the mechanisms by which the
location of these receptors promotes their coupling to speciﬁc
downstream signaling proteins and biochemical cascades.
2.2.2. GluN2A versus GluN2B in neuronal death and survival
The molecular cloning of NMDAR subunits has provided an
improved understanding of this receptor’s pharmacology, electro-
physiology, molecular biology, and cellular and physiological
properties. The NMDAR is composed of an essential GluN1 subunit
(also referred to as NR1) (Forrest et al., 1994; Moriyoshi et al.,
1991; Yamazaki et al., 1992), and the ionotropic property of the
receptor is fully established when it is coupled to at least one of the
GluN2A–D subunits (otherwise known as NR2A–D) (Ishii et al.,
1993; Kutsuwada et al., 1992; Meguro et al., 1992; Monyer et al.,
1992). The subunit composition of the NMDAR confers distinct
channel kinetics, agonist afﬁnity, and sensitivity to channel
blockers (Ishii et al., 1993; Kutsuwada et al., 1992; Monyer
et al., 1992), and NMDARs composed of different subunits are
expressed in different brain regions (Ishii et al., 1993; Kutsuwada
et al., 1992; Meguro et al., 1992; Monyer et al., 1992; Watanabe
et al., 1992). While the GluN1 subunit of the NMDAR is
ubiquitously located in the adult brain, the forebrain is populated
by NMDARs containing the GluN2A and the GluN2B subunits, and
the cerebellum is populated by NMDARs containing the GluN2A
and the GluN2C subunits (Ishii et al., 1993; Kutsuwada et al., 1992;
Meguro et al., 1992; Monyer et al., 1992; Watanabe et al., 1992).
Importantly, different NMDAR subunits can play distinct physio-
logical roles. Genetic deletion of GluN1 in mice completely
abolishes NMDAR activity, and the animals die soon after birth
(Forrest et al., 1994). Although GluN2A-knockout mice are viable,
they display impaired synaptic plasticity, such as long-term
potentiation (LTP) of synaptic efﬁcacy, and poor spatial memory
formation (Sakimura et al., 1995). In comparison, GluN2B-
knockout mice are less viable (Kutsuwada et al., 1996), except
when the knockout is speciﬁc to the pyramidal neurons of the
cortex and the CA1 hippocampus (Brigman et al., 2010), and they
display impaired long-term depression (LTD) and poor neuronal
development (Brigman et al., 2010; Kutsuwada et al., 1996). In
addition, many of the physiological roles of the NMDAR subunits
depend on their large and distinct cytoplasmic tails, and genetic
deletion of these C-terminal domains induces many of the features
Fig. 1. Distinct subpopulations of the NMDA receptor (NMDAR) mediate neuronal death and survival. (a) Under normal conditions, synaptic activity maintains neuronal
survival via activation of the synaptic NMDAR. This pro-survival effect is dependent on the calcium inﬂux through the receptors. (b) During cerebral ischemia, excessive
release of glutamate into the synapses and extrasynaptic sites causes global stimulation of NMDAR at both locations. The C-terminal domain of the GluN2B subunit acts as a
major hub for recruiting death-signaling proteins, which in turn is activated by calcium inﬂux through the receptors to induce neuronal death.
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(Sprengel et al., 1998). The protein machinery required for synaptic
plasticity, including proteins required for LTP and LTD, have been
demonstrated to interact directly with the C-terminal domains of
the GluN2A and GluN2B subunits of the NMDAR (Kim et al., 2005;
Krapivinsky et al., 2003).
The subunit composition of NMDARs is speciﬁc not only to
different regions of the brain but also to different subcellular
locations (Harney et al., 2008; Liu et al., 2007; Stocca and Vicini,
1998; Thomas et al., 2006; Tovar and Westbrook, 1999) and
changes dynamically throughout the process of brain development
(Flint et al., 1997; Monyer et al., 1994; Sheng et al., 1994;Watanabe et al., 1992) and during responses to physiological
stimuli (Bessho et al., 1994; Harney et al., 2008). In particular, the
cortical and hippocampal neurons in the neonatal forebrain
express GluN2B-containing NMDAR (GluN2BR) in both synapses
and extrasynaptic sites, whereas the cortical neurons in the adult
brain display an increased synaptic population of the GluN2A-
containing NMDAR (GluN2AR) (Flint et al., 1997; Kirson and Yaari,
1996; Liu et al., 2007; Stocca and Vicini, 1998; Thomas et al., 2006;
Tovar and Westbrook, 1999). By the adult age of P39–P92, the rat
hippocampus displays a profound reduction in the proportion of
functional GluN2BR, as measured by the degree of inhibition by
selective antagonists (Harris and Pettit, 2007). Most importantly,
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determinant of the differential effects of synaptic versus extra-
synaptic receptors. For example, synaptic and extrasynaptic
NMDARs have been demonstrated to govern different directions
of synaptic plasticity, with synaptic NMDARs mediating the LTP of
synaptic efﬁcacy and extrasynaptic NMDARs mediating the
opposing LTD (Lu et al., 2001). Notably, this ﬁnding can be
partially explained by the different NMDAR subtypes that are
present in these locations, with the GluN2AR subtype mediating
the LTP and the GluN2BR subtype mediating the LTD (Dalton et al.,
2012; Foster et al., 2010; Fox et al., 2006; Li et al., 2006; Liu et al.,
2004; Massey et al., 2004) (but see also Berberich et al., 2005;
Frizelle et al., 2006; Neyton and Paoletti, 2006; Weitlauf et al., 2005
for issues raised against the GluN2AR-speciﬁcity of NVP-AAM007
used in these and subsequent studies). Consistent with this ﬁnding,
the differential roles of synaptic and extrasynaptic NMDARs in
neuronal death and survival can also be partially explained by the
presence of distinct NMDAR subunits in these sub-cellular
locations (Fig. 1A and B). Selective GluN2BR antagonists are highly
neuroprotective in models of cerebral ischemia and other
neurodegenerative diseases (Chen et al., 2008; DeRidder et al.,
2006; Gotti et al., 1988; Graham et al., 1992; Liu et al., 2007;
O’Donnell et al., 2006; von Engelhardt et al., 2007; Zhou and
Baudry, 2006), whereas selective GluN2AR antagonists are poorly
neuroprotective and in several studies, exacerbated neuronal
death (Chen et al., 2008; DeRidder et al., 2006; Liu et al., 2007).
Importantly, in the adult rat forebrain, the GluN2AR and GluN2BR
NMDAR subtypes can confer neuronal survival and neuronal death,
respectively, independently of their subcellular location. Thus,
synaptic GluN2BR is sufﬁcient for the induction of neuronal death,
and synaptic GluN2AR protects neurons against excitotoxic
neuronal death mediated by synaptic GluN2BR (Liu et al., 2007).
Similarly, extrasynaptic GluN2AR is pro-survival and protects
neurons against extrasynaptic GluN2BR-induced and staurospor-
ine-induced neuronal death (Liu et al., 2007). Consistent with the
idea that NMDARs exert their subtype-speciﬁc outputs via their
distinct C-terminal domains (Foster et al., 2010; Sprengel et al.,
1998), replacing the C-terminus of GluN2B with that of GluN2A
prevents GluN2BR-mediated excitotoxicity in vitro and in vivo
(Martel et al., 2012). In contrast, replacing the C-terminus of
GluN2A with that of GluN2B converts the pro-survival GluN2AR
into an excitotoxic receptor (Martel et al., 2012). Taken together,
these ﬁndings indicate that GluN2AR in the adult neuronal synapse
confers activity-dependent neuronal survival signaling, while
GluN2BR in extrasynaptic sites contributes to excitotoxicity
following stroke and other neurodegenerative diseases (Fig. 1A
and B).
2.3. Excitotoxicity as the primary mechanism of ischemic damage
While many of the early studies concerning excitotoxicity
focused on public concerns about food safety, the search for
pharmacological inhibitors of the NMDARs becomes especially
motivating when mountains of evidence begin to point to the
major role of excitotoxicity in stroke and other neurodegenerative
diseases. The ﬁrst link between glutamate and stroke damage was
reported in 1959, when Van Harreveld found that topical
application of glutamate, which is abundant in brain extracts,
induced spreading depression in the rabbit brain. Based on this
observation, he proposed that glutamate might be involved in
similar cortical changes following stroke (Van Harreveld, 1959).
Subsequent studies have provided unequivocal evidence that
glutamate-mediated excitotoxicity is a primary contributor to
ischemic neuronal death. First, newly cultured hippocampal
neurons lacking synapses are resistant to oxygen deprivation for
up to 24 h, whereas mature cultured neurons with intact synapticconnections degenerate abruptly upon oxygen deprivation (Roth-
man, 1983). Importantly, attenuating synaptic activity, by either
reducing presynaptic release with tetrodotoxin or magnesium
chloride or inhibiting ionotropic glutamate receptors with the
antagonist gamma-D-glutamylglycine, prevents anoxic neuronal
death in mature cortical neurons (Rothman, 1983, 1984). These
data provide strong evidence that the synaptic release of glutamate
is required for anoxic damage. Second, intracerebral concentra-
tions of glutamate and aspartate increase abruptly in rats
subjected to cerebral ischemia (Benveniste et al., 1984; Drejer
et al., 1985; Hagberg et al., 1985), partially due to facilitated release
of the transmitters (Bosley et al., 1983) and to the dysfunction of
their uptake transporters (Drejer et al., 1985; Silverstein et al.,
1986). This 8-fold increase in extracellular neurotransmitter
release provides an explanation for the observation that the
abundant central neurotransmitter glutamate is normally benign
in the brain but induces excitotoxicity during cerebral ischemia.
Consistent with this ﬁnding, the removal of glutamatergic afferent
neurons attenuates neuronal death in rats subjected to cerebral
ischemia (Buchan and Pulsinelli, 1990; Johansen et al., 1986;
Jorgensen et al., 1987; Onodera et al., 1986). Third, intracerebral
injection of the NMDAR blocker 2-amino-7-phosphonoheptanoic
acid into the rat brain prevents neuronal death following cerebral
ischemia (Simon et al., 1984), providing the ﬁrst clear evidence
that glutamate, particularly its action on the NMDARs, is required
for ischemic brain damage. This ﬁnding has been replicated
extensively (Germano et al., 1987; Gill et al., 1987; Goldberg et al.,
1987; Ikonomidou et al., 1989a; McDonald et al., 1987; Olney et al.,
1989a; Rothman et al., 1987; Simon et al., 1986; Steinberg et al.,
1988, 1989; Weiss et al., 1986), and one of the most important
implications of this line of work is that drugs targeting the NMDAR
or the downstream signaling cascade are effective against stroke
damage. The enthusiasm is demonstrated by the large number of
clinical trials since (Tables 1 and 2).
2.3.1. Ischemic glutamate release and its inhibition
The ﬁrst step toward excitotoxicity during an acute episode of
stroke is the rapid elevation of glutamate levels in the ischemic
region of the brain (Benveniste et al., 1984; Dawson et al., 2000;
Drejer et al., 1985; Globus et al., 1988; Hagberg et al., 1985; Mitani
et al., 1990) (Fig. 1B). Thus, the inhibition of ischemic glutamate
release could confer neuroprotection by terminating multiple
downstream death signaling cascades at their converging up-
stream initiation point. The mechanism by which glutamate is
released is likely multi-factorial and depends on the severity of
stroke and the ischemic model used (Dawson et al., 2000; Drejer
et al., 1985; Rossi et al., 2000). This phenomenon can involve
synaptic release of glutamate due to excessive neuronal activity
and action potentials (Dawson et al., 2000; Drejer et al., 1985) or
potentiated release efﬁcacy (Bosley et al., 1983). In vitro, hypoxic
neuronal death can be inhibited by either tetrodotoxin (TTX), an
inhibitor of voltage-gated sodium channels that inhibits action
potentials, or magnesium, which inhibits synaptic glutamate
release (Rothman, 1983). As a result, a number of sodium channel
blockers, including BW1003C87 and sipatrigine (BW619C89), have
been designed to prevent ischemic glutamate release, and these
molecules effectively reduce the elevation of glutamate levels and
the neuronal death that follow cerebral ischemia in vivo (Gaspary
et al., 1994; Graham et al., 1993; Leach et al., 1993; Lekieffre and
Meldrum, 1993; Meldrum et al., 1992; Okiyama et al., 1995). In
addition, magnesium ions and the N-type calcium channel
antagonist ziconotide (SNX-111; Prialt), which both prevent
synaptic glutamate release, are efﬁcacious against cerebral
ischemic damage (Okiyama et al., 1995; Valentino et al., 1993).
Ischemic glutamate release can also involve the impairment or
reversal of the glutamate uptake system, resulting in spillover
Table 1
Inhibiting glutamate release in stroke patients.
Clinical trial Patient
population
Outcome
Na+ channel blocker
Lifarizine (RS-87476) Phase II 117 Treatment within 12 h of ischemic stroke results in favorable trend toward improvement
in mortality and morbidity.
The treatment was well tolerated, with no serious side effects.
Squire et al. (1995)
Sipatrigine (BW619C89) Phase II 48 + 27 Treatment within 12 h of stroke failed to improve outcome compared to placebo.
Several side effects were observed: nausea and vomiting, irritation at the injection site,
reduced consciousness, agitation, confusion, and hallucination.
Muir et al. (1995, 2000)
N-type Ca2+ channel blocker
Ziconotide (SNX-111; Prialt) Approved for the treatment of chronic pain.
Status of the stroke clinical trial is unclear.
Magnesium sulfate Phase III 2589 Treatment within 12 h of acute stroke failed to improve mortality and morbidity.
The treatment was well tolerated, with no serious side effects.
Muir et al. (2004)
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(Dawson et al., 2000; Drejer et al., 1985; Phillis et al., 2000) or
neuronal origins (Drejer et al., 1985; Phillis et al., 2000; Rossi et al.,
2000; Sanchez-Prieto and Gonzalez, 1988; Silverstein et al., 1986).Table 2
Antagonism of NMDA receptor in stroke patients.
Clinical trial Patient popula
Competitive: glutamate-binding site
Selfotel (CGS 19755) Phase II 389 + 87 
Midafotel (CPPene; SDZ EAA 494) Preliminary trial
with seizure patients
Competitive: glycine-binding site
Licostinel (ACEA 1021) Phase I 64 
Gavestinel (GV150526) Phase III 109 + 1804 + 13
Uncompetitive or non-competitive
Aptiganel (CNS 1102) Phase II/III 628 
AR-R15896AR Phase II 175 + 103 
Dextrorphan HCl (Ro 01-6794/706) Phase I 67 
Remacemide HCl Phase II 61 In addition to their role in ischemic glutamate release, these
glutamate uptake transporters are also essential for glutamate re-
uptake and clearance during normal synaptic transmission and
following ischemia–reperfusion (Colleoni et al., 2008). Thus,tion Outcome
Treatment within 6 h of acute ischemic stroke increased mortality due
to brain insult and failed to improve morbidity.
Several side effects were observed: agitation, hallucinations, confusion,
paranoia, and delirium.
Davis et al. (1997) and Grotta et al. (1995)
Intolerable side effects were observed: poor concentration, sedation,
ataxia, dysarthria, depression, and amnesia.
Sveinbjornsdottir et al. (1993)
Treatment within 48 h of ischemic stroke failed to improve outcome
compared to placebo, despite reaching plasma concentration optimal
for neuroprotection in animal studies.
The treatment was well tolerated, with no serious side effects.
Albers et al. (1999)
67 Treatment within 6 h of acute stroke failed to improve mortality and
morbidity.
The treatment was well tolerated, with no serious side effects.
Anon. (2000), Lees et al. (2000) and Sacco et al. (2001)
Treatment within 6 h of hemispheric ischemic stroke exacerbated
mortality and morbidity.
Several side effects were observed: hypertension, ventricular
arrhythmia, cerebral edema, stupor, and confusion.
Albers et al. (2001)
Treatment within 12 or 24 h of acute stroke had no effect on morbidity
(preliminary ﬁnding).
Several side effects were observed: dizziness, vomiting, nausea, fever,
stupor, agitation, and hallucination.
Diener et al. (2002) and Lees et al. (2001a)
Treatment within 48 h of ischemic stroke had no effect on morbidity
(preliminary ﬁnding).
Several side effects were observed: nystagmus, somnolence, nausea,
vomiting, change in blood pressure, agitation, confusion, and
hallucination.
Albers et al. (1995)
The optimal neuroprotective dose cannot be achieved in early hours
with the maximum well-tolerated dose.
Several side effects were observed: nausea and vomiting, irritation at
the injection site, headache, dizziness, tremor, agitation, confusion,
somnolence, and hallucination.
Dyker and Lees (1999)
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uptake system induces excitotoxicity (Rothstein et al., 1993, 1996).
In addition, gene-deletion of the glial glutamate transporters GLT-1
and GLAST exacerbates ischemic neuronal death (Rao et al., 2001)
and other forms of excitotoxicity (Tanaka et al., 1997; Watase et al.,
1998), while increased expression of GLT-1 protects neurons
against ischemic injury (Rothstein et al., 2005). Importantly, the
new transporter inhibitor hydroxy-tetrahydro-pyrrolo-isoxazole
carboxylic acid (HIP), which selectively inhibits reverse glutamate
uptake rather than glutamate uptake (Funicello et al., 2004), is
protective against ischemic neuronal death (Colleoni et al., 2008).
In comparison, the general glutamate transporter inhibitor DL-
threo-benzyloxyaspartic acid (DL-TBOA) and nonselective high
doses of HIP are not neuroprotective and can exacerbate ischemic
neuronal death (Colleoni et al., 2008).
The inhibition of ischemic glutamate release allows for the
termination of ischemic stroke-induced excitotoxicity at its most
upstream initiation point. In addition, these agents have the
beneﬁt of inhibiting ischemic glutamate release by blocking
reverse uptake while potentiating physiological glutamate trans-
mission by blocking glutamate uptake. Unlike NMDAR antagonists,
which produce neurotoxicity in some non-ischemic brain regions
like the cingulate and the retrosplenial cortex, these agents are
considerably safer (Graham et al., 1993). However, no feasible
treatment candidates from this line of drugs have passed the
rigorous clinical testing required for broad clinical use (Table 1).
Lifarizine (RS-87476), which decreases glutamate release by
modulating voltage-gated sodium and calcium currents, has
shown promise in Phase II trials when administered to patients
within 12 h of acute stroke (Squire et al., 1995). However, no
follow-up studies have been reported. The previously mentioned
sodium channel blocker sipatrigine caused nausea, vomiting, and
severe neurological side effects in Phase II stroke trials, preventing
further clinical investigations (Muir et al., 1995, 2000). Magnesium
ions, which can both hinder presynaptic glutamate release and
antagonize the NMDAR uncompetitively, failed to reduce mortality
or morbidity when administered to 2589 patients within 12 h of
stroke in a Phase III trial (Muir et al., 2004). The N-type calcium
channel antagonist ziconotide, which protects the rat brain against
cerebral ischemia by reducing ischemic glutamate release
(Valentino et al., 1993), has been approved and marketed for
the treatment of chronic pain, but its status in stroke clinical trials
remains unclear.
2.3.2. NMDAR antagonists and calcium channel blockers
The critical role of NMDAR-mediated calcium inﬂux in stroke
pathogenesis suggests that NMDAR antagonists and post-synaptic
calcium channel blockers may be effective against stroke (Choi,
1995). Notably, calcium accumulation occurs before and is a strong
predictor of neuronal death following cerebral ischemia (Desh-
pande et al., 1987). Thus, protection against neuronal hypoxia in
vitro and cerebral ischemia in vivo can be achieved by direct
NMDAR antagonism (Goldberg et al., 1987; Rothman et al., 1987;
Simon et al., 1984; Weiss et al., 1986), antagonism of the AMPA
receptor, which is required for NMDAR activation (Sheardown
et al., 1990), simultaneous antagonism of both the NMDAR and
AMPA receptor (Germano et al., 1987; Goldberg et al., 1987;
Rothman, 1984; Simon et al., 1986), antagonism of the L-type
calcium channels, which can contribute to calcium overload
(Uematsu et al., 1989), and intracellular calcium chelation
(Tymianski et al., 1993c). In general, direct NMDAR antagonism
appears to be sufﬁciently neuroprotective against hypoxic neuro-
nal death compared to co-antagonism of different excitotoxic
receptors (Goldberg and Choi, 1993; Goldberg et al., 1987) and
calcium sources (see Section 2.2). It is worth mentioning that
ketamine, phencyclidine, and dextromethorphan, three drugs thatare commonly used in humans, are uncompetitive NMDAR
antagonists that are neuroprotective in models of ischemic/anoxic
neuronal death (Goldberg et al., 1987; Rothman et al., 1987;
Steinberg et al., 1988, 1989; Weiss et al., 1986). The drug MK-801 is
a potent and selective uncompetitive NMDAR antagonist that
readily crosses the blood–brain barrier, allowing systemic
administration (Foster and Wong, 1987; Wong et al., 1986).
Notably, MK801 is one of the most widely studied NMDAR
antagonists in neurodegeneration research, and has been widely
demonstrated to be effective in in vitro and in vivo models of
ischemic/anoxic neuronal death (Gill et al., 1987; Goldberg and
Choi, 1993; Ikonomidou et al., 1989a; Lo et al., 1994; McDonald
et al., 1987; Olney et al., 1989a; Park et al., 1988). Two other
notable compounds are the NMDAR glycine-binding site antago-
nists gavestinel (GV150526) and licostinel (ACEA1021) (Bordi
et al., 1997; Woodward et al., 1995), which were developed with
the intent of reducing the side effects that are observed with
conventional NMDAR antagonists that target the glutamate-
binding site or the NMDAR channel pore (Chiamulera et al.,
1990; Hargreaves et al., 1993). Like conventional NMDAR
antagonists, gavestinel and licostinel are strongly protective
against ischemic neuronal damage in vivo (Bordi et al., 1997;
Pearlstein et al., 1998; Reggiani et al., 2001; Takaoka et al., 1997;
Warner et al., 1995). Taken together, the experimental evidence
demonstrates the potential for NMDAR antagonism, whether it is
competitive or uncompetitive or occurs via inhibition of the
glutamate-binding site, the glycine-binding site, or the channel
pore, in the treatment of ischemic stroke damage.
Like the drugs designed to prevent ischemic glutamate release
(see Section 2.3.1), none of the drugs designed to target the NMDAR
directly have been approved for clinical use in stroke treatment,
and several of these compounds have failed clinical studies in
unexpected ways (Table 2). The reason for this lack of clinical
success is likely multi-factorial. As previously reported (Lai et al.,
2011), two possible explanations are that (1) NMDAR blockers
produce many side effects due to the prevalence of neurological
functions requiring these receptors and (2) NMDAR blockers have a
short therapeutic window for drug administration, as they are
effective only when administered before or immediately following
stroke. A major drawback of NMDAR antagonists is their side
effects, including the dysfunction of neurological processes that
require the NMDAR and the reversible induction of pathology
related to neuronal morphology. Indeed, a number of NMDAR
antagonists that were under development have been discontinued
from further human clinical studies, partially due to concerns
about pathomorphological changes that were observed in neurons
from animals treated with the earlier experimental compounds
like MK-801 and phencyclidine (Olney et al., 1989b, 1991).
Consistent with ﬁndings obtained in animal studies, NMDAR
antagonists that bind to the glutamate-binding site and the
channel pore cause sedation and psychotomimetic side effects in
human subjects (Albers et al., 1995; Diener et al., 2002; Dyker and
Lees, 1999; Grotta et al., 1995; Lees et al., 2001a; Sveinbjornsdottir
et al., 1993). In some studies, the optimal neuroprotective plasma
concentration of NMDAR antagonists cannot be achieved in a
timely manner when they are administered to patients at the
maximum well-tolerated dose (Dyker and Lees, 1999; Sveinb-
jornsdottir et al., 1993). In other studies, the optimal neuropro-
tective plasma concentration that was observed in animal models
of stroke is achieved in human subjects, but clinical efﬁcacy is
lacking. This ﬁnding may be due to the delayed treatment that is
typical in clinical settings (Albers et al., 1999; Diener et al., 2002).
Antagonists that target the NMDAR glycine-binding site are well-
tolerated and lack the above mentioned side effects, including
pathomorphological changes and neurological dysfunction, in both
animal studies (Chiamulera et al., 1990; Hargreaves et al., 1993)
Table 3
Inhibiting GluN2B-containing NMDA receptors and the death-signaling cascades downstream of the NMDA receptor in stroke patients.
Clinical trial Patient population Outcome
GluN2B/NMDAR antagonist
Eliprodil (SL-82.0715) Phase III 114 Trial suspended due to lack of efﬁcacy, and side effects make neuroprotective
concentrations unlikely.
Concerns with electrocardiographic effects.
Reviewed by Doble (1999) and Lees (1997)
Traxoprodil (CP-101,606) Phase II 53 + 30 + 404 Open-label: treatment within 12 h of traumatic brain injury or hemorrhagic
stroke showed above-average outcome.
Bullock et al. (1999)
Double-blind: treatment within 12 h of traumatic brain injury or hemorrhagic
stroke showed no difference between drug and placebo.
Merchant et al. (1999)
Double-blind: treatment within 8 h of traumatic brain injury improved
mortality and morbidity at 6 months.
Yurkewicz et al. (2005)
In all studies, the treatment was well tolerated, with no serious side effects
GluN2B-PSD95–nNOS interaction
NA-1 Phase II 185 Treatment initiated after the completion of endovascular aneurysm repair
surgery resulted in signiﬁcantly fewer ischemic infarction (iatrogenic stroke).
The treatment was well tolerated, with no serious side effects.
Hill et al. (2012)
Multiple mechanisms
Lubeluzole Phase III 721 + 725 + 1786 Treatment within 6 h of acute ischemic stroke had no effect on mortality and
morbidity.
The treatment was well tolerated.
Diener (1998), Diener et al. (2000) and Grotta (1997)
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2001b; Sacco et al., 2001). However, patients receiving these
compounds demonstrated no improvement in stroke outcome
(Anon., 2000; Albers et al., 1999; Lees et al., 2001b; Sacco et al.,
2001). Thus, it appears that among experimental compounds that
target the NMDAR, the side effects or lack of side effects that are
observed in animal studies are a strong predictor of clinical side
effects and drug tolerance, but the neuroprotective efﬁcacy that is
observed in animal models of stroke has failed to translate into
clinical efﬁcacy.
2.3.3. Selective GluN2BR antagonists and targeting NMDAR signaling
proteins
A hallmark of conventional NMDAR antagonism is the
generation of psychomimetic side effects, which are a major cause
of clinical failure. In addition, as in animal studies (Ikonomidou
et al., 2000; Liu et al., 2007), NMDAR antagonism can worsen
clinical stroke outcome in some trials (Albers et al., 2001; Davis
et al., 1997; Lees et al., 2001b). Given the pivotal role of the
GluN2AR in neuronal function, including the LTP of synaptic
efﬁcacy (Liu et al., 2004; Massey et al., 2004; Sakimura et al., 1995)
and NMDAR-mediated neuronal survival signaling (see Section
2.2.2), there may be several advantages of selectively inhibiting the
GluN2BR and its downstream death signaling pathways. In
particular, ifenprodil and related compounds are a distinct class
of NMDAR antagonists that act non-competitively at the GluN2BR
with high subunit-speciﬁcity (Fischer et al., 1997; Gallagher et al.,
1996; Kew et al., 1996; Malherbe et al., 2003; Priestley et al., 1994;
Williams, 1993; Williams et al., 1993). These GluN2B-selective
compounds have been shown to be effective against ischemic
neuronal death in vitro and in vivo (Chen et al., 2008; DeRidder
et al., 2006; Gotti et al., 1988; Graham et al., 1992; Liu et al., 2007;
O’Donnell et al., 2006; von Engelhardt et al., 2007; Zhou and
Baudry, 2006), and they are not associated with the neurological
side effects that are commonly seen with conventional NMDAR
antagonists (Blanchet et al., 1999; Jackson and Sanger, 1988). In
addition, like glycine-binding site antagonists, these compounds
do not induce the pathomorphological changes in the rat brain thatare characteristic of conventional NMDAR antagonists (Duval et al.,
1992). Two ifenprodil derivatives, eliprodil (SL-82.0715) and
traxoprodil (CP-101,606), have been demonstrated to cause no
neurological side effects, and traxoprodil has been demonstrated
to have therapeutic efﬁcacy in small double-blinded placebo-
controlled Phase II studies (Bullock et al., et al., 1999; Merchant
et al., 1999; Yurkewicz et al., 2005). A Phase III trial for this drug is
currently underway (Table 3). While the clinical use of eliprodil in
stroke management can be of cardiovascular concern due to its
nonspeciﬁc effects on other ion channels, traxoprodil has been
found to be safe and tolerable (Bullock et al., 1999; Merchant et al.,
1999; Yurkewicz et al., 2005).
Although selective inhibitors of the pro-death GluN2BR
circumvent nonspeciﬁc blockade of the pro-survival GluN2AR
and appear to lack the clinical side effects seen with conventional
NMDAR antagonists, these treatments could have clinical limita-
tions for similar reasons. First, in addition to their role in
excitotoxicity, these pro-death receptors have important physio-
logical functions, such as their roles in the extinction of fear
memory, the manifestation of stress responses, and the learning of
new memory. Thus, even with the most selective GluN2BR
antagonists, some adverse neurological effects may be overlooked
when low doses are used in small clinical trials that would
manifest when larger (and more effective) doses are used to treat a
larger patient population. Second, like nonspeciﬁc NMDAR
blockers, ifenprodil-related drugs are only effective when admin-
istered immediately following stroke, and they quickly lose their
efﬁcacy when treatment is delayed. In an animal model of focal
ischemic stroke, the highly selective GluN2BR antagonist Ro 25-
6981 is neuroprotective when administered prior to, but not 4.5 h
after, the onset of ischemia (Liu et al., 2007). This limited time
window for effective drug administration makes NMDAR antago-
nists, whether or not they are selective for the GluN2B-containing
NMDAR subtype, therapeutically impractical. In an effort to
circumvent these limitations, recent studies have attempted to
target death signals downstream of the NMDAR, rather than the
receptor itself (see Section 4 and Table 3). Because there are many
cellular signaling proteins downstream of the NMDAR, it is
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responsible for NMDAR-mediated excitotoxicity and those that are
responsible for important physiological functions. By speciﬁcally
targeting downstream death signaling proteins, and avoiding
signaling proteins with other functions, it may be possible to
develop therapeutics that are as effective as NMDAR blockers with
fewer side effects. In addition, because of the sequential nature of
signaling cascades, blocking downstream death signals may allow
for a wider or delayed window for effective treatment compared to
receptor blockers.
3. The NMDAR and neuronal survival signaling pathways
In the non-excitotoxic brain, the NMDAR is critical for neuronal
development and the maintenance of neuronal survival post-
development, and in the ischemic or traumatized brain, certain
subpopulation of the NMDAR is neuroprotective (see Section 2.2)
and plays an important role in the recovery of neurological
functions. As discussed in Section 2.2, the NMDAR subpopulation
in the synapse that contains the GluN2A subunit tends to promote
neuronal survival, while the receptor subpopulation in extra-
synaptic sites that contains the GluN2B subunit tends to promote
neuronal death. This ﬁnding partially explains how this notorious
death-associated receptor can be a major player in neuronal
survival and neuroprotection under both physiological and
pathological conditions. Thus, in some neurons cultured in vitro,
NMDAR stimulation promotes neuronal survival (Balazs et al.,
1988a,b, 1989; Didier et al., 1989), and NMDAR inhibition induces
neuronal death (Brenneman et al., 1990a,b). Similarly, in the
rodent brain in vivo, GluN2AR stimulation in particular and
synaptic activity in general decreases spontaneous (physiological)
neuronal death and protects the brain against excitotoxic injury
(Chen et al., 2008; Liu et al., 2007; Yao et al., 2012; Young et al.,
1999), while NMDAR inhibition induces neuronal death in the
developing brain (Adams et al., 2004; Gould et al., 1994;
Ikonomidou et al., 1999) and hinders recovery of the injured
brain (Ikonomidou et al., 2000). Importantly, stimulation of theFig. 2. The phospholipid pathways leading to neuronal death and survival. Synaptic a
activation of the survival-promoting protein kinase Akt. Phosphorylative activation of Akt
to the phosphatidylinositol (3,4,5)-triphosphate (PIP3), a phospholipid product of
phosphatidylinositol (4,5)-bisphosphate (PIP2, orange colored). The activated Akt transl
ischemia, the death-promoting protein lipid and protein phosphatase known as phosphat
into PIP2 to terminate Akt activity. PTEN also directly bind to the C-terminal domain of
translocates into nucleus to induce neuronal death in a GluN2B subunit-dependent 
phosphatidylinositol (3,4)-bisphosphate, is excitotoxic by recruiting the death-promoti
PIP2 into phosphatidylinositol monophosphate (PIP) by inositol polyphosphate 
dephosphorylation can also be catalyzed by PTEN, this ﬁnding can in part explain the GluN2AR survival signaling pathway appears to be the primary
mechanism by which ischemic preconditioning of the brain, a
highly effective regimen for increasing the tolerance of the brain to
subsequent ischemic injury, protects the brain against stroke
damage (Chen et al., 2008; Terasaki et al., 2010), and direct
stimulation or expression of the synaptic NMDAR in general or the
GluN2AR in particular protects the brain from excitotoxic injury in
rodent models of ischemic stroke (Liu et al., 2007; Yao et al., 2012).
3.1. Survival signaling by Akt
The NMDAR promotes neuronal survival via the activation of
the protein kinase Akt (Bhave et al., 1999; Lafon-Cazal et al., 2002;
Yano et al., 1998; Zhang et al., 1998). The cellular Akt (c-Akt), also
known as protein kinase B (PKB) and protein kinase related to the A
and C kinases (rac), is a serine threonine protein kinase that is
homologous to the viral oncogene product v-Akt (Bellacosa et al.,
1991; Coffer and Woodgett, 1991; Jones et al., 1991). One
mechanism by which the NMDAR induces Akt activation is via
calcium-dependent tyrosine phosphorylation of insulin receptor
substrate-1 (IRS-1), which subsequently binds to and activates the
well characterized pro-survival protein phosphatidylinositol 3-
kinase (PI3K) (Zhang et al., 1998), which is critical for the
phosphorylative activation of Akt (Alessi et al., 1996; Burgering
and Coffer, 1995; Cross et al., 1995; Franke et al., 1995; Kohn et al.,
1996) (Fig. 2). Active PI3K phosphorylates phospholipids in the cell
membrane to generate phosphatidylinositol (3,4)-bisphosphate
(PtdIns(3,4)P2) and phosphatidylinositol (3,4,5)-triphosphate
(PtdIns(3,4,5)P3), which bind to the pleckstrin homology (PH)
domain of Akt, facilitating its dimerization and phosphorylative
activation (Datta et al., 1995, 1996; Franke et al., 1995, 1997; Frech
et al., 1997; Klippel et al., 1997; Stephens et al., 1998; Stokoe et al.,
1997), which result in PI3K/Akt mediated neuronal survival
signaling (Dudek et al., 1997; Kauffmann-Zeh et al., 1997; Kulik
et al., 1997). Alternatively, the NMDAR can directly activate Akt via
a non-canonical mechanism that involves calcium-dependent
activation of the calcium–calmodulin dependent protein kinasectivity induces neuronal survival in part by NMDA receptor (NMDAR)-mediated
 can occur via several pathways, and the best characterized one involves Akt binding
 phosphatidylinositol 3-kinase (PI3K) generated from the plasma membrane
ocates into the nucleus, a process known to promote cell survival. During cerebral
ase and tensin homolog deleted on chromosome ten (PTEN) de-phosphorylates PIP3
 the GluN1 subunit in GluN2B-containing NMDARs to augment excitotoxicity, and
manner. Recently, it is demonstrated that a different form of PIP2 (red colored),
ng GluN2B subunit of the NMDAR into the synapse. Dephosphorylation of this bad
phosphatase 4A (INPP4A) is neuroprotective. Since this survival-promoting
mechanism by which nuclear translocation of PTEN is excitotoxic.
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Consistent with the survival-promoting role of synaptic NMDAR,
basal PI3K/Akt survival signaling depends on ongoing synaptic
activity and activation of the synaptic NMDAR (Sutton and
Chandler, 2002), and augmented PI3K/Akt activity can be triggered
by increased synaptic NMDAR stimulation (Papadia et al., 2005;
Soriano et al., 2006). Importantly, stimulation of the PI3K/Akt
pathway via the NMDAR or other mechanisms is neuroprotective
against hypoxic and excitotoxic neuronal death in vitro (Jo et al.,
2012; Soriano et al., 2006; Yamaguchi et al., 2001) and ischemic
neuronal death in vivo (Endo et al., 2006; Jo et al., 2012; Kawano
et al., 2001; Noshita et al., 2003), and inhibition of the PI3K/Akt
pathway exacerbates ischemic neuronal death (Endo et al., 2006;
Noshita et al., 2001). In addition, cerebral ischemia induces
neuronal death in part by inhibiting Akt activity (Kawano et al.,
2001; Yano et al., 2001), and ischemic preconditioning confers
resistance to further ischemic challenge by stimulating Akt (Miao
et al., 2005; Yano et al., 2001).
Although the essential role of Akt in NMDAR-mediated
neuronal survival signaling has been well established, the exact
mechanism by which Akt promotes survival remains unclear.
Several mechanisms by which PI3K/Akt promotes neuronal
survival have been reported. For instance, Akt phosphorylates
and thereby inhibits the death-signaling protein kinase glycogen
synthase kinase-3 (GSK3) (Cross et al., 1995; van Weeren et al.,
1998), and this is an important mechanism by which the NMDAR
and PI3K/Akt promote survival of neurons and other cell types
(Cross et al., 2001; Crowder and Freeman, 2000; Endo et al., 2006;
Hetman et al., 2000; Pap and Cooper, 1998; Soriano et al., 2006).
Consistent with the role of PTEN in terminating PI3K/Akt activity
during excitotoxicity (Ning et al., 2004) (see also Section 3.1.1),
GSK3 contributes to excitotoxic neuronal injury and inhibition of
GSK3 protects neurons against excitotoxicity (Facci et al., 2003;
French and Heberlein, 2009; Kelly et al., 2004). Other mechanisms
by which PI3K/Akt promotes neuronal survival include Akt-
mediated phosphorylation and inhibition of the death-signaling
BCL-2 family member BAD (Datta et al., 1997; Noshita et al., 2002;
Yano et al., 1998), the forkhead transcription factor FKHR (Abid
et al., 2004; Kawano et al., 2002; Nakae et al., 1999, 2000; Soriano
et al., 2006; Trotman et al., 2006), and the proline-rich Akt
substrate (PRAS) (Kovacina et al., 2003; Saito et al., 2004). In
addition, the ﬁnding that Akt translocates to the nucleus soon after
its activation at the plasma membrane suggests that many of its
targets are nuclear rather than cytosolic (Andjelkovic et al., 1997;
Borgatti et al., 2003; Meier et al., 1997; Pekarsky et al., 2000).
Nuclear Akt is required for its tumorigenic activity, and speciﬁc
inhibition of nuclear Akt by dephosphorylation prevents tumori-
genesis (Trotman et al., 2006). Finally, PI3K/Akt survival signaling
may also be induced by BDNF (Bhave et al., 1999; Zheng and
Quirion, 2004; Zhu et al., 2002). Thus, the NMDAR can induce the
release of BDNF via the CREB-signaling pathway (see Section 3.2),
indirectly inducing neuronal Akt activation. At least one study has
demonstrated that appreciable Akt activation is observed only
after prolonged NMDAR stimulation that is sufﬁcient to induce
BDNF expression and that NMDAR-mediated Akt activation is
blocked by an antagonist to the BDNF receptor Trk (Bhave et al.,
1999).
3.1.1. Inhibition of neuronal survival by nuclear and cytosolic PTEN
While the PI3K–Akt pathway mediates NMDAR survival
signaling, the opposing phosphatase and tensin homolog deleted
on chromosome ten (PTEN) pathway mediates NMDAR-induced
death signaling. PTEN, also known as mutated in multiple
advanced cancers 1 (MMAC1) and TGF-beta-regulated and
epithelial cell-enriched phosphatase 1 (TEP1), is a tumor
suppressor that is mutated in multiple types of cancer cells (Liand Sun, 1997; Li et al., 1997; Steck et al., 1997) and mediates its
apoptotic effects primarily via dephosphorylation of
PtdIns(3,4,5)P3 at its 3-position, which terminates the PI3K–
Akt signaling pathway (Maehama and Dixon, 1998; Myers et al.,
1998; Stambolic et al., 1998). Consistent with its role opposing
PI3K/Akt survival signaling, the introduction of PTEN inhibits cell
growth and survival, and the mutation of PTEN confers cell
resistance to a variety to apoptotic stimuli (Furnari et al., 1997;
Groszer et al., 2001; Li et al., 2002; Stambolic et al., 1998). In
addition, the expression of PTEN has been correlated with certain
forms of neuronal death (Kyrylenko et al., 1999) and sensitizes
neurons to excitotoxic neuronal death in vitro and in vivo (Gary
and Mattson, 2002). Interestingly, PTEN forms a death-signaling
complex with the NMDAR (Fig. 2). Consistent with the death-
signaling role of GluN2BR, PTEN directly interacts with the
cytoplasmic tail of the GluN1 subunit of GluN2BR but not that of
GluN2AR (Ning et al., 2004). In contrast to the lipid phosphatase
activity of PTEN that is known to terminate PI3K-to-Akt signaling,
the protein phosphatase activity of PTEN is required for the
potentiation of extrasynaptic NMDAR current (Ning et al., 2004).
Knockdown of PTEN expression restores PI3K/Akt signaling and
dampens extrasynaptic NMDAR current. These effects contribute
to neuroprotection via independent mechanisms, leading to
substantial protection against ischemic neuronal death in vitro
and in vivo (Ning et al., 2004). Interestingly, while PTEN directly
potentiates the GluN2BR-dependent neuronal death-signaling
pathway that leads to neuronal injury, it can also indirectly
potentiate the GluN2AR-mediated neuronal survival-signaling
pathway via a PTEN-induced kinase 1 (PINK1)-dependent
mechanism (Chang et al., 2010). In contrast to modulation of
the NMDAR by PTEN, the NMDAR can also exert its effect directly
by modulating PTEN nuclear translocation (Zhang et al., 2013;
Zheng et al., 2012). Consistent with the recently reported critical
role of nuclear PTEN in the induction of apoptosis and growth
inhibition (Liu et al., 2005; Song et al., 2011; Trotman et al., 2007),
excitotoxic stimulation of the NMDAR triggers nuclear transloca-
tion of PTEN in a GluN2B-dependent manner, resulting in a
marked decrease in nuclear PtdIns(3,4,5)P3 and nuclear Akt
phosphorylation in injured neurons (Zhang et al., 2013). In
contrast, GluN2AR not only fails to induce PTEN nuclear
translocation (Zhang et al., 2013) but also impairs the nuclear
translocation of PTEN (Zheng et al., 2012). GluN2AR-mediated
impairment of PTEN translocation can confer neuroprotection, in
part via the up-regulation of nuclear TAR DNA-binding protein-43
(TDP-43) (Zheng et al., 2012). Likewise, the inhibition of PTEN
nuclear translocation via the interference peptide Tat-K13 (K13:
KEIVSRNKRRYQED), whose sequence ﬂanks the critical lysine-13
mono-ubiquitination site that is required for PTEN nuclear
translocation (Trotman et al., 2007; Walker et al., 2004), protected
neurons from GluN2BR-mediated excitotoxic neuronal death
(Zhang et al., 2013). Importantly, the Tat-K13 peptide, which is
rendered membrane-permeable by the Tat sequence from the
membrane transduction domain of the HIV1 Tat protein (Tat:
GRKKRRQRRR), protected the rat brain from ischemic stroke
damage even when administered up to 6 h post-ictus.
3.1.2. Excitotoxicity mediated by PtdIns(3,4)P2
In marked contrast to the neuronal survival signaling that is
mediated by the PtdIns(3,4,5)P3-Akt pathway, the other PI3K
product, PtdIns(3,4)P2, exerts excitotoxic effects by potentiating
NMDAR-induced death signaling (Sasaki et al., 2010) (Fig. 2). Direct
application of PtdIns(3,4)P2 or gene-deletion of the synapse-
enriched PtdIns(3,4)P2 phosphatase inositol polyphosphate phos-
phatase 4A (INPP4A) renders neurons susceptible to NMDAR-
mediated excitotoxicity, in part via recruitment of the death-
promoting GluN2B subunit from the extrasynaptic site into the
Fig. 3. Synaptic activity mediates prolonged neuronal survival via a positive feedback loop between CREB and BDNF. Synaptic activity promotes neuronal survival in part by
NMDA receptor (NMDAR)-mediated phosphorylative activation of cyclic adenosine monophosphate response element (CRE) binding protein (CREB). The phosphorylated
CREB binds to the CREB-binding protein (CBP) to regulate the transcription of CRE-responsive genes. One survival gene that is unregulated is brain-derived neurotrophic
factor (BDNF), and BDNF release mediated by NMDAR stimulation and BDNF activation of the Trk receptor can further promote CREB activation. During cerebral ischemia,
stimulation of the extrasynaptic NMDARs induces a CREB shut-off pathway, leading to neuronal death.
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mice that lack INPP4A or express a mutant INPP4A that lacks
phosphatase activity exhibit substantial neurodegeneration in
the striatum and related behavioral deﬁcits, even in the absence
of any exogenous excitotoxic input (Sasaki et al., 2010).
Interestingly, PTEN is also a phosphatase for PtdIns(3,4)P2, and
this activity is comparable to its phosphatase activity for
PtdIns(3,4,5)P3 (Myers et al., 1998). Given that PtdIns(3,4)P2
confers excitotoxicity via its effect on the synapse, this ﬁnding
could partially explain why translocation of PTEN into the
nucleus, and away from the synapse and the cytoplasm, is
excitotoxic (see Section 3.1.1). Consistent with the death-
signaling role of this non-canonical PI3K product, a recent study
reported that PI3K is required for NMDAR-mediated and GluN2B-
dependent stimulation of the NADPH oxidase and the production
of superoxide (Brennan-Minnella et al., 2013). In this study,
direct application of the supposedly pro-survival PtdIns(3,4,5)P3,
which has no direct effect on superoxide production, facilitated
NMDAR-mediated superoxide production independent of PI3K
(Brennan-Minnella et al., 2013). Because PtdIns(3,4,5)P3 is also a
substrate for the production of PtdIns(3,4)P2 (Lioubin et al.,
1996), the apparently contradictory death-signaling effect of
PtdIns(3,4,5)P3 could be due to its conversion to the excitotoxic
PtdIns(3,4)P2.
3.2. CREB-mediated regulation of neuronal survival
NMDAR-mediated survival signaling is transcription-depen-
dent, and the primary transcription factor involved in this process
is likely the cyclic adenosine monophosphate response element
(CRE) binding protein (CREB) (but see also NFI-A in Section 4.2.1).
The activation of the NMDAR, particularly via synaptic activity,
induces prominent activation of both CREB and its co-activator
CREB-binding protein (CBP), resulting in the transcription of many
CREB-responsive genes (Deisseroth et al., 1996; Hardingham et al.,
2001a,b; Hardingham et al., 2002; Hu et al., 1999; Impey et al.,2002; Mabuchi et al., 2001; Monti et al., 2002) (Fig. 3). While the
phosphorylative activation of CREB at serine-133 can occur via
multiple mechanisms (Gonzalez and Montminy, 1989; Mayr and
Montminy, 2001), its activation by the NMDAR involves (Hard-
ingham et al., 2001a,b): (1) the faster-acting calmodulin kinase IV
(CaMKIV) of the calmodulin-dependent protein kinase family
(Sheng et al., 1991) and (2) the slower-acting ERK-mediated
activation of the p90 ribosomal S6 kinase Rsk-2 (De Cesare et al.,
1998; Xing et al., 1996). Thus, neuronal activity-dependent CREB
activation depends on the CaMKIV pathway in the ﬁrst hour, with
the ERK pathway prolonging CREB activation by more than an hour
(Hardingham et al., 2001a; Wu et al., 2001). The requirement for
ERK in NMDAR-mediated CREB signaling raises the possibility that
long-lasting NMDAR-mediated ERK survival signaling involves
CREB as a major player. In addition, consistent with its long-lasting
activity, neuroprotection after a brief episode of synaptic NMDAR
activity is long-lasting, and the delayed-phase, but not the acute-
phase, of neuroprotection is dependent on CREB signaling (Papadia
et al., 2005). Consistent with the essential role of CBP in CREB-
mediated transcription (Arias et al., 1994; Chrivia et al., 1993;
Kwok et al., 1994), synaptic NMDAR activation induces a
prominent increase in nuclear calcium, leading to the CaMKIV-
mediated phosphorylative activation of CBP at serine-301, which
promotes CREB/CBP dependent transcription (Chawla et al., 1998;
Hardingham et al., 1997, 2001b; Hu et al., 1999; Impey et al., 2002).
Most importantly, the activation of CREB and CREB-mediated
transcription are required for NMDAR-dependent and other
neurotrophic factor-dependent neuronal survival during develop-
ment and in adulthood (Hansen et al., 2004; Lonze et al., 2002;
Mantamadiotis et al., 2002; Monti et al., 2002) and can render
neurons resistant to excitotoxicity and other apoptotic stimuli
(Bonni et al., 1999; Hardingham et al., 2002; Mabuchi et al., 2001;
Papadia et al., 2005; Riccio et al., 1999; Soriano et al., 2006; Walton
et al., 1996, 1999). Finally, in addition to the set of genes that are
directly regulated by CREB, CREB can also confer synaptic NMDAR-
mediated neuronal survival signaling by regulating the expression
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expression of activating transcription factor 3 (ATF3), which acts as
a transcription repressor for death-signaling genes and thereby
protects neurons against excitotoxic and ischemic neuronal death
in vitro and in vivo (Zhang et al., 2011).
3.2.1. BDNF and other CREB-promoted gene products
Synaptic and extrasynaptic NMDARs affect the transcription
of independent sets of largely non-overlapping genes and as
such, mediate transcription-dependent neuronal survival and
death, respectively (Lau and Bading, 2009; Leveille et al., 2010;
Papadia et al., 2008; Qiu et al., 2013; Zhang et al., 2007). CREB
appears to be the primary transcription factor involved in the
transcriptional regulation of genes that are required for neuronal
survival, and the inhibition of CREB signaling by the extra-
synaptic NMDAR likely contributes to excitotoxicity (Harding-
ham et al., 2002; Tan et al., 2012). Among the pro-survival genes
that are upregulated by CREB, BDNF has been extensively
characterized, and it is critical to NMDAR/CREB-mediated
neuronal survival signaling (Favaron et al., 1993; Hansen et al.,
2004; Shieh et al., 1998; Tao et al., 1998). The transcription-
dependent production of BDNF in the brain is neuronal activity-
dependent and requires calcium inﬂux through the NMDAR
(Favaron et al., 1993; Ghosh et al., 1994; Zafra et al., 1991) or
other calcium channels (Ghosh et al., 1994). The potentiation of
synaptic activity by dis-inhibition of neurons and environmental
enrichment promotes BDNF transcription (Hardingham et al.,
2002; Young et al., 1999; Zafra et al., 1991), and inhibition of the
NMDAR but not inhibition of the other ionotropic glutamate
receptors prevents BDNF transcription (Favaron et al., 1993;
Hardingham et al., 2002; Zafra et al., 1991). Consistent with the
ﬁnding that distinct sub-populations of the NMDAR mediate
neuronal death and neuronal survival (see Section 2.2), NMDARs
in the synapse that contain the GluN2A subunit are primarily
responsible for neuronal activity-dependent BDNF gene expres-
sion (Chen et al., 2007). In contrast, synaptic GluN2BR has no
effect on BDNF gene expression (Chen et al., 2007), and
extrasynaptic NMDAR has been shown to inhibit CREB-mediated
BDNF gene expression (Hardingham et al., 2002). Importantly,
the release of BDNF and subsequent activation of the Trk receptor
can induce further BDNF production via an ERK-dependent
signaling cascade (Bonni et al., 1999; Hu et al., 1999; Riccio et al.,
1999), resulting in a positive-feedback loop that promotes long-
lasting neuroprotection following a brief episode of NMDAR
stimulation (Jiang et al., 2005). Consistent with the requirement
for BDNF in NMDAR-mediated survival signaling, this neuro-
trophic factor exerts neuroprotective effects in vitro and in vivo
(Alderson et al., 1990; Hofer and Barde, 1988; Hyman et al., 1991;
Knusel et al., 1992; Morse et al., 1993; Widmer et al., 1993), and
the absence of this factor leads to neurodegeneration in response
to the depletion of NMDAR activity (Hansen et al., 2004). During
focal ischemic stroke, BDNF is released into the brain in response
to cerebral ischemia as a self-protective mechanism (Comelli
et al., 1992), and this release requires activation of the NMDAR
(Comelli et al., 1992), speciﬁcally the NMDAR subtype that
contains the GluN2A subunit (Chen et al., 2008). Thus, exogenous
administration of BDNF into the rat brain is strongly neuropro-
tective against focal ischemic stroke damage (Zhang and
Pardridge, 2001).
4. The NMDAR and neuronal death signaling pathways
In view of the primary role of the NMDAR in excitotoxic
neuronal injury following ischemic stroke and other neurodegen-
erative diseases, several pharmacological treatments have been
developed to prevent excitotoxic glutamate release during cerebralischemia (Table 1), to antagonize the NMDAR competitively or
uncompetitively (Table 2), or to inhibit receptors that contain the
GluN2B subunit (Table 3). These compounds target the NMDAR at
the membrane surface receptor level (or at points further
upstream), leading to a short time window for effective drug
administration. Thus, drugs that target excitotoxic glutamate
release are no longer effective once glutamate is released into the
ischemic brain, and drugs that antagonize the NMDAR or other
excitotoxic receptors are no longer effective once these receptors
and their downstream death signaling proteins are activated. In
addition to excitotoxic death signaling proteins, there are a variety
of other NMDAR signaling proteins that are responsible for normal
neuronal functions. These include signaling proteins with impor-
tant roles in learning and memory, cognitive processing, motiva-
tion and rewards, and neuronal survival. As a result, NMDAR
antagonists typically cause intolerable side effects, such as
psychotomimetic effects, memory deﬁcits, sedative effects, and
exacerbation of stroke outcome, in both animal models and stroke
patients (Tables 1–3). In the past decade, a number of studies have
attempted to identify the precise death-signaling mechanisms or
proteins that are downstream of the NMDAR and elucidate the
mechanisms by which these downstream events contribute to
excitotoxic neuronal death following ischemic stroke. By develop-
ing novel treatments that inhibit these downstream targets, it may
be possible to overcome many of the clinical limitations that are
observed with conventional treatments that target the NMDAR
death-signaling cascade at the receptor level. Drugs that target
delayed death-signaling events or proteins, speciﬁcally those that
are activated several hours or days following stroke, can remain
efﬁcacious in the stroke clinic even when treatment is delayed. In
addition, drugs that target death-signaling events or proteins that
have no acute physiological functions should lack the severe side
effects that are observed with conventional NMDAR blockers.
4.1. The cytoplasmic tail of the NMDAR
Because NMDAR death signaling requires an inﬂux of calcium
ions (see Section 2.1.1) and the NMDAR is more neurotoxic than
other sources of calcium (see Section 2.1.2), it has been postulated
that the excitotoxic neuronal death-signaling protein must be
closely associated with, if not physically bound to, the NMDAR
(Tymianski et al., 1993b). Consistent with this theory, the
cytoplasmic tail of the NMDAR is a major hub for signaling
proteins, and direct protein–protein interactions between the
cytoplasmic tail of the NMDAR and its associated signaling
proteins confer many of the known NMDAR functions (Kim
et al., 2005; Krapivinsky et al., 2003; Li et al., 2006). In addition,
genetic deletion of the NR2 cytoplasmic tail results in the subtype-
speciﬁc loss of NMDAR function (Sprengel et al., 1998), and
swapping the cytoplasmic tail of one NMDAR subunit with that of
another NMDAR subunit modiﬁes the functional output of the
receptor accordingly (Foster et al., 2010). Importantly, swapping
the cytoplasmic tail of GluN2A with that of GluN2B converts the
pro-survival receptor into an excitotoxic receptor, while swapping
the cytoplasmic tail of GluN2B with that of GluN2A prevents
excitotoxicity in vitro and in vivo (Martel et al., 2012). Many
neuronal death-signaling proteins are known to bind directly to
the cytoplasmic tail of the NMDAR (Ning et al., 2004; Tu et al.,
2010; Wang et al., 2003), and other death-signaling proteins
associate with the NMDAR indirectly by binding the PSD95 (see
Section 4.2) (Aarts et al., 2002; Sattler et al., 1999). These proteins
include PTEN (see Section 3.1.2), which binds to the GluN1 subunit
(Ning et al., 2004), cyclin-dependent kinase 5 (cdk5) (see Section
4.3.1), which binds to the GluN2A subunit (Wang et al., 2003), and
death-associated protein kinase 1 (DAPK1) (see Section 4.1.1),
which binds to the GluN2B subunit (Tu et al., 2010). Notably, the
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can be especially pronounced following cerebral ischemia (Tu
et al., 2010; Zhou et al., 2010). This increased binding may partially
explain the observation that the NMDAR is benign and promotes
neuronal survival under normal conditions but becomes abruptly
excitotoxic under pathological conditions, such as stroke (Fig. 1A
and B). Importantly, disruption of the binding of NMDAR to death-
signaling proteins using an interference peptide that mimics the
amino-acid sequence of the NMDAR cytoplasmic tail prevents
excitotoxic neuronal death following ischemia in vitro and in vivo,
without affecting NMDAR channel activity or other downstream
signaling proteins (Aarts et al., 2002; Sattler et al., 1999; Tu et al.,
2010; Wang et al., 2003). By disrupting the excitotoxic output but
not the functional output downstream of the NMDAR, these
interference peptides have the potential to confer therapeutic
efﬁcacy in the stroke clinic without the intolerable neurological
side effects that are observed with conventional NMDAR blockers
that target surface receptors.
4.1.1. DAPK1 is the predominant protein recruited to the NMDAR
DAPK1 is of particular interest because a recent quantitative
proteomic analysis of the death-signaling proteins that are
recruited to the cytoplasmic tail of the NMDAR during cerebral
ischemia revealed DAPK1 as the most prevalent protein (Tu et al.,
2010) (Fig. 4). DAPK1 is a 160-kDa calmodulin-dependent serine/
threonine protein kinase whose phosphorylation activity is known
to be responsible for certain forms of apoptotic cell death (Cohen
et al., 1997, 1999; Deiss et al., 1995; Kissil et al., 1997). Under basal
conditions, inactive DAPK1 is subject to a negative-feedback loop
that results in autophosphorylation at serine-308 of its calmodu-
lin-binding domain, rendering DAPK1 insensitive to calmodulin-
binding and preventing its death-promoting function (Shohat
et al., 2001). In response to apoptotic stimuli, such as cerebral
ischemia or NMDAR-mediated excitotoxicity (Shamloo et al.,
2005), DAPK1 is dephosphorylated and its death-promoting
activity resumes (Shamloo et al., 2005; Shohat et al., 2001). One
mechanism by which cerebral ischemia induces activation of
DAPK1 is via NMDAR-mediated calcineurin activation, which
subsequently induces the dephosphorylation and activation of
DAPK1, leading to ischemic neuronal death (Shamloo et al., 2005).
Consistent with this ﬁnding, inhibition of the NMDAR or
calcineurin prevents dephosphorylation of DAPK1 in culturedFig. 4. Excitotoxicity recruits death-associated protein kinase 1 (DAPK1) to the cytoplasm
the NMDA receptor (NMDAR) induces calcineurin-mediated dephosphorylation and activ
of the GluN2B subunit of NMDAR, and augments the activity of the receptor to promot
regulated kinase (ERK) at serine-735, and this phosphorylation induces neuronal death
activity of ERK.neurons in an in vitro model of ischemia, and inhibition of DAPK1
prevents ischemic neuronal death in vitro and in vivo (Shamloo
et al., 2005). Interestingly, the pro-survival nuclear signaling factor
ERK, which is downstream of the NMDAR, can directly interact
with DAPK1, leading to ERK-mediated phosphorylation of DAPK1
at serine-735 and enhancing DAPK1 death-signaling activity (Chen
et al., 2005). Thus, the NMDAR can also stimulate DAPK1 via the
NMDAR–ERK signaling pathway (see Section 3.1.1) (Kim et al.,
2005; Krapivinsky et al., 2003). Importantly, this DAPK1–ERK
interaction causes ERK to be retained in the cytoplasm and
prevents its pro-survival nuclear signaling, further enhancing the
propensity for neuronal death (Chen et al., 2005). Once activated
following cerebral ischemia, DAPK1 is recruited to the NMDAR,
where it binds to the cytoplasmic tail of GluN2B at residues 1292–
1304 (NR2B-CT: KKNRNKLRRQHSY) (Tu et al., 2010). This GluN2B–
DAPK1 interaction leads to phosphorylation of GluN2B at serine-
1303, which potentiates the NMDAR channel current. Disruption of
this GluN2B–DAPK1 interaction using the interference peptide Tat-
NR2B-CT, whose Tat sequence represents the membrane trans-
duction domain of the HIV1 Tat protein to allow membrane
permeability, prevents DAPK1-mediated GluN2B phosphorylation
and potentiation of the NMDAR current in vitro and excitotoxic
neuronal death in a mouse model of ischemic stroke in vivo (Tu
et al., 2010). In addition, reversal of the ischemia-induced
phosphorylation of serine-1303 by protein phosphatase 1 (PP1)
also reverses the ischemic potentiation of NMDAR activity and
results in neuroprotection in primary hippocampal neurons
subjected to oxygen–glucose deprivation (Farinelli et al., 2012).
4.2. PSD95/nNOS: the nitric oxide pathway
In neurons, the NMDAR is particularly effective at inducing
calcium/calmodulin-dependent nNOS-mediated production of
nitric oxide (Garthwaite et al., 1988), and this effect is calcium
source-speciﬁc (Kiedrowski et al., 1992). Several lines of biochem-
ical analysis have elucidated the mechanism underlying this
calcium source-speciﬁcity. The GluN2A–D subunit of the NMDAR
binds directly to PSD95 and several other members of the
membrane-associated guanylate kinase (MAGUK) family (Bren-
man et al., 1996b; Kornau et al., 1995; Muller et al., 1996;
Niethammer et al., 1996) (Fig. 5A). PSD95 contains three PDZ
domains for binding to PDZ ligands. The PDZ1 and the PDZ2ic tail of the GluN2B subunit. During cerebral ischemia, inﬂux of calcium ion through
ation of DAPK1 at serine-308. The activated DAPK1 binds to the C-terminal domain
e excitotoxicity. In addition, DAPK1 can be phosphorylated by extracellular signal-
 directly by augmenting DAPK1 activity and by hindering the survival-promoting
Fig. 5. The postsynaptic density protein 95 (PSD95) brings neuronal nitric oxide synthase (nNOS) into close proximity with the NMDA receptor (NMDAR) channel pore. (a)
Under normal conditions, synaptic activity promotes neuronal survival in large by activation of the NMDAR. In addition, protein residues are protected from S-nitrosylation by
forming disulﬁde bonds. (b) During cerebral ischemia, GluN2B subunit of the NMDAR forms a death-signaling complex with PSD95 and nNOS, leading to calcium-dependent
production of the superoxide anion (O2) and nitric oxide (NO*). The formation of peroxynitrite (ONOO) from O2 and NO* can induce neuronal injury via a number of
mechanisms. In addition, the NO* congener nitrosonium cation (NO+) can induce S-nitrosylation of free cysteine residues in proteins when the disulﬁde bonds are broken
under oxygen deprivation. S-nitrosylation has been shown to induce neuronal death both by activating death-signaling proteins and inhibiting survival-promoting proteins.
(c) The GluN2B–PSD95–nNOS death signaling complex can be disrupted using the peptides NR2B9c and Tat-NR2B9c, which is rendered membrane permeable by inclusion of
the membrane transduction domain sequence from the HIV1 Tat protein. In addition, this complex can be disrupted using recently developed small molecules ZL006 and
IC87201.
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serine-X-valine-COOH (T/SxV) motif of PDZ ligands, including the
C-termini of all four GluN2 subunits and some GluN1 splice
variants (Kornau et al., 1995). The PDZ2 domain of PSD95 also
binds to the N-terminal linker of neuronal nitric oxide synthase
(nNOS) (Brenman et al., 1996a; Hillier et al., 1999; Tochio et al.,
2000). Simultaneous binding of PSD95 to the NMDAR and nNOS
brings nNOS into close proximity with the NMDAR channel pore
and ensures efﬁcient activation of nNOS by the calcium that ﬂuxes
through the NMDAR (Christopherson et al., 1999; Sattler et al.,
1999). This ﬁnding has important implications for excitotoxicity
and ischemic brain damage, because inhibiting nNOS activity by
gene-deletion or by pharmacological means prevents NMDAR-
mediated excitotoxicity in cultured neurons (Brorson et al., 1995;
Dawson et al., 1991, 1993, 1996) and attenuates cerebral infarct
and behavioral deﬁcit in animals subjected to cerebral ischemia
(Huang et al., 1994). Likewise, the direct application of nitric oxide
donors to cultured neurons is potently neurotoxic (Dawson et al.,
1991; Lipton et al., 1993). Mice in which exon2 of nNOS is
disrupted express a catalytically active nNOS that lacks the PDZ
domain and thus cannot interact with PSD95 (Brenman et al.,
1996a). These mice are resistant to ischemic stroke damage (Huang
et al., 1994). Consistent with the ﬁnding that PSD95 is required for
NMDAR-mediated production of neurotoxic nitric oxide, knock-
down of PSD95 using anti-sense mRNA attenuates both NMDAR-
mediated nitric oxide production and NMDAR-mediated excito-
toxicity (Sattler et al., 1999). The indirect interaction of nNOS with
the NMDAR provides an explanation for the observation thatcalcium inﬂux from NMDARs is especially neurotoxic and an
underlying mechanism for the distinct calcium pathway hypothe-
sis for excitotoxicity (Sattler et al., 1998; Tymianski et al., 1993b).
In addition, a recent study demonstrated that the NMDAR–PSD95–
nNOS interaction is augmented following cerebral ischemia (Zhou
et al., 2010) (Fig. 5A and B). This speciﬁc priming of the NMDAR for
excitotoxicity during ischemia may explain why the NMDAR is
especially neurotoxic during ischemia.
4.2.1. Neuronal death mediated by nitric oxide
Nitric oxide can exist in its native free radical form (NO*), as a
nitrosonium cation (NO+), and as a nitrotroxyl anion (NO). There
are a number of mechanisms by which this gaseous molecule
induces neuronal death, but they can be largely differentiated by
the congener in question (Fig. 5B). For example, the free radical
form of nitric oxide can react with the superoxide anion to form the
highly reactive molecule peroxynitrite (ONOO), which triggers
lipid peroxidation and damage. Importantly, early work comparing
different nitric oxide congeners suggested that peroxynitrite is the
primary nitric oxide derivative responsible for nitric oxide-
mediated neurotoxicity (Lipton et al., 1993). Interestingly, nNOS
can be a major source of superoxide anion (Xia et al., 1996),
especially when the level of L-arginine decreases, such as during
excitotoxicity (Parathath et al., 2007). Consistent with the primary
role of peroxynitrite in nNOS death signaling, preventing
superoxide formation prevents nNOS-dependent cell death in
vitro and excitotoxic neuronal damage in vivo (Dawson et al., 1993,
1996; Lipton et al., 1993; Parathath et al., 2007; Xia et al., 1996). In
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activation of poly(ADP-ribose) polymerase 1 (PARP-1) is a critical
mechanism leading to excitotoxic and ischemic neuronal death
(Eliasson et al., 1997; Goto et al., 2002; Mandir et al., 2000; Zhang
et al., 1994). In addition to causing energy deprivation with
depletion of ATP and NAD, poly(ADP-ribose) polymer production
by PARP-1 induces neuronal death by triggering the mitochondrial
release and nuclear translocation of the apoptosis-inducing factor
(AIF) (Wang et al., 2004; Yu et al., 2002, 2006). Consistent with the
cytotoxic actions of the poly(ADP-ribose) polymer, its sequestra-
tion by the NMDAR survival-signaling protein Iduna leads to
neuroprotection against excitotoxic and ischemic neuronal injury
in vitro and in vivo (Andrabi et al., 2011) (see also Kang et al., 2011
for other cytoprotective mechanisms of Iduna). In addition to
damages to DNA and other biomolecules, peroxynitrite activates a
deadly current from transient receptor potential cation channel
M7 (TRPM7) in neurons subjected to oxygen–glucose deprivation
(Aarts et al., 2003). Knockdown of TRPM7 using siRNA prevents
anoxic neuronal death in cortical neurons (Aarts et al., 2003), and
knockdown of TRPM7 using a lentivirus carrying a shRNA that
targets TRPM7 mRNA prevents hippocampal neuronal death in rats
subjected to global cerebral ischemia (Sun et al., 2009). In contrast
to the nitric oxide free radical, the nitrosonium cation preferen-
tially promotes thiol group-nitrosylation (S-nitrosylation) of free
cysteine residues on target proteins, leading to their activation,
deactivation, or inactivation. This phenomenon is especially
important during oxygen deprivation, as disulﬁde bonds (in their
oxidized form) are reduced into individual free thiol-groups (in
their reduced form), making them targets for nitric oxide-
mediated S-nitrosylation (Takahashi et al., 2007). Recent evidence
demonstrated that protein S-nitrosylation stimulates activation of
death-signaling pathways and inhibition of survival-signaling
pathways in cortical neurons subjected to excitotoxicity by direct
NMDAR stimulation.
A comprehensive review of the evidence supporting the role of
S-nitrosylation in neuronal death is outside the scope of this
review, so we present here a brief summary of the ﬁndings that are
directly relevant to NMDAR-mediated excitotoxicity. S-nitrosyla-
tion of enzymes can either stimulate or inhibit catalytic activity.
For example, S-nitrosylation of matrix metalloprotease-9 (MMP-
9) leads to the activation of downstream cell death signaling
cascades and contributes to neuronal death in neurons subjected
to NMDAR stimulation (Manabe et al., 2005) and cerebral
infarction in rats subjected to 2 h of focal ischemia (Gu et al.,
2002). In both cases, the excitotoxic damage can be prevented by
nNOS gene-knockout or MMP inhibition (Gu et al., 2002; Manabe
et al., 2005). In addition, S-nitrosylation of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) is required for its interaction
with Siah1, which promotes the nuclear translocation of GAPDH
that is essential for excitotoxic neuronal injury (Hara et al., 2005).
Moreover, NMDAR and nNOS-mediated S-nitrosylation of the
GluK2 (GluR6) subunit of the kainate receptor facilitates its
interaction with PSD95 and mixed-lineage kinase-3 (Yu et al.,
2008), which subsequently leads to neuronal death following
focal ischemic stroke (Yu et al., 2009), global cerebral ischemia
(Pei et al., 2006), and other forms of excitotoxic neuronal death
(Liu et al., 2006). More recently, S-nitrosylation of dynamin-
related protein 1 (Drp1) was shown to contribute to mitochon-
drial ﬁssion, synaptic loss, and neuronal death in neurodegenera-
tive diseases (Cho et al., 2009). In contrast to its role in the
stimulation of neuronal death signaling, S-nitrosylation of
protein–disulphide isomerase inhibits its neuroprotective activi-
ty in neurons subjected to NMDAR stimulation (Uehara et al.,
2006), and S-nitrosylation of src homology-2 domain-containing
phosphatase (SHP-2) inhibits its ERK-dependent neuronal sur-
vival signaling and contributes to NMDAR-mediated excitotoxicneuronal death in vitro and ischemic neuronal death in vivo (Shi
et al., 2013).
It is worth noting that NMDAR-to-nNOS signaling may involve a
mix of neuroprotective effects in addition to neurotoxic effects. For
instance, NMDAR-mediated release of nitric oxide is required for
neuronal survival signaling by the transcription factor nuclear
factor I-A (NFI-A) (Gonzalez-Zulueta et al., 2000; Zheng et al.,
2010), and this is one mechanism by which ischemic pre-
conditioning confers neuroprotection (Gonzalez-Zulueta et al.,
2000). When selectively removing this beneﬁcial effect of nNOS by
gene deletion of NFI-A, mice became especially susceptible to
excitotoxicity (Zheng et al., 2010). Thus, selective targeting of
nNOS death-signaling pathways may be more neuroprotective
than directly targeting nNOS, which would also block the survival-
signaling pathways. Finally, while the NMDAR promotes protein S-
nitrosylation by releasing nitric oxide via the PSD95–nNOS
pathway, the activity of the NMDAR is subject to feedback-
regulation by this process (Lipton et al., 1993; Takahashi et al.,
2007). In particular, the GluN2A subunit of the NMDAR is inhibited
by S-nitrosylation under conditions of low oxygen supply
(Takahashi et al., 2007), and this inhibition likely accounts for
the depression of synaptic NMDAR activity following oxygen–
glucose deprivation (Aarts et al., 2003). Although this anoxic
suppression of NMDAR activity was once widely believed to be an
evolutionarily favored mechanism by which the brain protects
itself from excessive NMDAR stimulation during stroke (Lipton
et al., 1993), recent evidence indicating that the GluN2A-contain-
ing NMDAR subpopulation promotes survival highlights the need
for further research on this subject.
4.2.2. The Tat-NR2B9c peptide and clinical success
Disrupting the interaction between the NMDAR and nNOS has
several therapeutic advantages over pharmacological inhibition of
either or both of these molecules. As discussed earlier in this
review, the NMDAR has several important functions in the brain,
and as a result, NMDAR blockers failed to be clinically useful due to
excessive side effects. Like the NMDAR, nNOS has several
important physiological functions in the brain (Irikura et al.,
1995; Nelson et al., 1995). Thus, it would be ideal to disrupt
NMDAR-mediated nNOS activation without affecting normal
NMDAR function or normal nNOS activity. This goal can be
achieved by targeting PSD95. Knockdown of PSD95 using antisense
mRNA attenuates NMDAR-mediated nitric oxide production and
excitotoxicity (Sattler et al., 1999), but this strategy has no effect on
NMDAR channel conductance and/or calcium loading or non-
NMDA-dependent activation of nNOS (e.g., via voltage-gated
calcium channels) (Sattler et al., 1999). In addition, disrupting
the NMDAR–PSD95 interaction by loading neurons with NR2B9c
(Fig. 5C), a small interference peptide that resembles the last 9
amino acid residues of the GluN2B C-terminal domain (Kornau
et al., 1995), has no effect on NMDAR current (Sattler et al., 1999)
but protects neurons against NMDAR-mediated excitotoxicity
(Aarts et al., 2002). Both of these strategies allow for the inhibition
of NMDAR/nNOS-mediated neuronal damage while leaving native
NMDAR function and nNOS activity intact.
When the NR2B9c peptide is rendered membrane permeable by
fusion with the membrane transduction domain of the HIV1 Tat
protein, the new fusion peptide Tat-NR2B9c (Fig. 5C), which also
disrupts NMDAR-mediated nNOS activation and excitotoxicity
without affecting NMDAR current and calcium loading (Aarts et al.,
2002), has the potential to be administered intravenously in rats
subjected to focal ischemia, in other in vivo stroke models, and in
human patients to treat stroke in the clinic. Consistent with the
ﬁnding that non-excitotoxic NMDAR function is unaltered by this
peptide, Tat-NR2B9c has no effect on NMDAR-dependent synaptic
plasticity or neuronal survival signaling (Martel et al., 2009;
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or 90 min of transient focal ischemia, a single dose of Tat-NR2B9c
(3 nmol/g, i.v., 1 or 3 h post-ischemia onset), but not the control
peptide Tat-NR2B9c-AA, reduced infarct volume and improved
neurological outcome for up to 62 d (Aarts et al., 2002; Sun et al.,
2008). In gyrencephalic non-human primates subjected to 90 min,
3.5 h, or 4.5 h of transient focal ischemia, Tat-NR2B9c (2.6 mg/kg,
i.v., 1 or 3 h post-ischemia onset) reduced MRI-measured infarct
volume and non-human primate stroke scale (NHPSS)-based
neurological outcome for up to 30 d (Cook et al., 2012b). In
addition, in a preclinical study using non-human primates that
modeled the design of the parallel and concurrent human clinical
study ENACT (Evaluating Neuroprotection in Aneurysm Coiling
Therapy), Tat-NR2B9c (2.6 mg/kg, i.v.) reduced the number and the
volume of embolic stroke infarcts, as measured by T2-weighted
MRI (Cook et al., 2012a). Most importantly, the recently reported
outcome of the ENACT clinical trial (ClinicalTrial.gov
NCT00728182) demonstrated that Tat-NR2B9c (NA-1, 2.6 mg/kg,
i.v.) reduced the number of iatrogenic ischemic infarcts in patients
receiving endovascular repair for intracranial aneurysm (Hill et al.,
2012) (Table 3). After a multitude of clinical failures (Tables 1–3),
this ﬁnding lends strong support to the theory that NMDAR-based
treatment is indeed clinically feasible for the management of
stroke and for the ﬁrst time, demonstrates clinically that successful
stroke intervention can be accomplished by targeting death-
signaling events that occur downstream of the NMDAR.
4.2.3. Noncanonical mechanism of Tat-NR2B9c: inhibition of the
PSD95–nNOS interaction
While the neuroprotective efﬁcacy of the Tat-NR2B9c peptide
has been consistently demonstrated in both pre-clinical tests using
a variety of animal models and clinical trials in patients, the
detailed mechanisms by which the peptide exerts its activity
remain unclear. Given that the T/SxV motif of the NMDAR binds to
several other members of the MAGUK family (Brenman et al.,
1996b; Kornau et al., 1995; Muller et al., 1996; Niethammer et al.,
1996), it is not surprising that the Tat-NR2B9c peptide can disrupt
more than just the GluN2B–PSD95 interaction (Cui et al., 2007).
However, among a group of PDZ-domain containing proteins that
includes many of the MAGUKs, PSD95 and nNOS appear to be the
most neurotoxic (Cui et al., 2007). Thus, although PSD95 binds to
many other signaling proteins downstream of the NMDAR, the
neuroprotective effect observed upon knockdown of PSD95 and
administration of Tat-NR2B9c is likely due to the disruption of
NMDAR-mediated nNOS activation, rather than the disruption of
other downstream signaling cascades. In a recent screen of
protein–protein interactions speciﬁcally disrupted by Tat-NR2B9c,
it was demonstrated that Tat-NR2B9c preferentially disrupts the
PSD95(PDZ2)–nNOS interaction with a potency (IC50 at 0.2 mM)
an order of magnitude higher than that required for disruption of
other PDZ–domain interactions, including that of GluN2A–
PSD95(PDZ2) (IC50 at 0.5 mM), GluN2B–PSD95(PDZ2) (IC50 at
8 mM), and GluN2C–PSD95(PDZ2) (IC50 at 0.75 mM) (Cui et al.,
2007). This ﬁnding suggests that the Tat-NR2B9c peptide is more
effective at disrupting the PSD95–nNOS interaction than the
intended GluN2B–PSD95 interaction. However, it should be
cautioned that this study used the PDZ2 domain as a source of
GluN2B interaction, whereas in the NMDAR–PSD95–nNOS signal-
ing complex, the interaction presumably occurs between NMDAR–
PSD95(PDZ1), as the PDZ2 domain would be occupied by nNOS.
Inconsistent with the higher potency observed for Tat-NR2B9c
against the GluN2A–PSD95(PDZ2) interaction than the GluN2B–
PSD95(PDZ2) interaction that was observed in this study (Cui et al.,
2007), Tat-NR2B9c disrupts the GluN2B–PSD95–nNOS interaction
but not the GluN2A–PSD95–nNOS interaction in the rat
forebrain (Aarts et al., 2002). Regardless, the ﬁnding that thePSD95(PDZ2)–nNOS interaction can be disrupted at an IC50 of
0.2 mM (Cui et al., 2007) suggests that Tat-NR2B9c, at a reasonable
dose (3 nmol/g), acts in part by disrupting the PSD95–nNOS
interaction. This high potency may also provide an explanation
for the observation that Tat-NR2B9c is neuroprotective in rats
subjected to ischemic stroke even when administered at very low
doses (0.03, 0.3, and 1 nmol/g; 3 h post-stroke) (Sun et al., 2008).
4.2.4. Small molecule mimetics for interference peptides
Interference peptides such as Tat-NR2B9c have several clinical
disadvantages compared to conventional small drug compounds,
including poor pharmacokinetics, limited administration routes,
expensive production cost, and immunological concerns (Lai and
Wang, 2010). To overcome these pitfalls, several studies have
attempted to identify small drug compounds that can mimic the
effects of the interference peptides. A high throughput screen of a
150,000-compound library identiﬁed several small molecules that
effectively disrupted the PSD95–nNOS interaction, and one of
these compounds was further modiﬁed to yield IC87201 (Fig. 5C),
which has an IC50 of 31 mM (Florio et al., 2009). Notably, IC87201
disrupts the PSD95–nNOS interaction without affecting the
interaction of PSD95 with other proteins. This ﬁnding raises the
intriguing possibility that interference peptides like Tat-NR2B9c
can be mimicked using small molecular compounds. In addition, it
may be possible to design these small molecules to achieve a high
speciﬁcity for the disruption of a particular protein–protein
interaction without affecting related protein–protein interactions.
More recently, an independent study designed and synthesized the
de novo small molecule ZL006 based on the presumable structural
requirements of the PSD95–nNOS interaction (Tochio et al., 2000)
(Fig. 5C), and this molecule has high speciﬁcity and potency for
disrupting the PSD95–nNOS interaction without noticeable effects
on the interaction of PSD95 with other proteins (Zhou et al., 2010).
Consistent with the effect of Tat-NR2B9c on excitotoxic and
ischemic neuronal injury, ZL006 is neuroprotective against
NMDAR-mediated excitotoxicity in vitro and ischemic neuronal
injury in vivo (Zhou et al., 2010). ZL006 readily crossed the blood–
brain barrier, a potential limitation for interference peptides and
neuroprotective proteins (Chen et al., 2013; Yen et al., 2013), when
administered intravenously and had no effect on NMDAR channel
function, nNOS activity, or related neurological functions, such as
learning and memory (Zhou et al., 2010). Interestingly, the
structures of IC87201 and ZL006 are highly similar, suggesting
that the two compounds may act via the same mechanism and
reconﬁrming the possibility that molecules with this type of two-
ring structure can disrupt the PSD95–nNOS interaction. Future
structure–activity relationship studies using these two compounds
and other related compounds may allow for the development of
compounds that are even more potent than IC87201 and ZL006.
4.3. The calpain pathway
The diverse proteolytic functions performed by calpains, a
group of enzymes collectively named due to their calcium-
dependent (cal-) cysteine endopeptidase activity (-pain) (Murachi
et al., 1980), are involved in NMDAR/calcium-mediated neuronal
damage (Fig. 6). These signaling proteases, which were initially
isolated in the rat brain (Guroff, 1964), include a number of distinct
isoforms that are either tissue-speciﬁc or ubiquitously expressed
in animal cells (Murachi, 1983). There are at least two forms of
calpain, which differ according to their sensitivity to activation by
calcium (Mellgren, 1980), and each form contains a catalytic
subunit of approximately 80 kDa (Ohno et al., 1984) and a
regulatory subunit of approximately 30 kDa (Sakihama et al.,
1985). NMDAR stimulation speciﬁcally activates the neuron-
speciﬁc calpain I, but not the more ubiquitous calpain II, in the rat
Fig. 6. Calpain mediates excitotoxicity via protein cleavage. GluN2B-containing NMDA receptors can induce neuronal injury by calcium-dependent activation of the death-
promoting protease calpain. Calpain-mediated truncation of the C-terminal domain of the metabotropic glutamate receptor 1 (mGluR1), which promotes neuronal survival
via activation of the long form of phosphoinositide 3 kinase enhancer (PIKE-L), converts the receptor into a death-signaling receptor. In addition, calpain-mediated truncation
of p35, which promotes neuronal survival by cdk5-dependent activity, into p25 induces aberrant target redirection of cdk5 to induce neuronal death. Finally, calpain-
mediated truncation of striatal-enriched protein tyrosine phosphatase 61 (STEP61), which inhibits death-signaling by p38 of the mitogen-activated protein kinase family,
into the inactive STEP33 contributes to excitotoxic neuronal death.
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activation has been demonstrated to be the primary mechanism by
which cerebral hypoxia and/or ischemia triggers proteolysis in the
brain (Arai et al., 1991; Lee et al., 1991; Seubert et al., 1989),
depression of synaptic efﬁcacy (Arlinghaus et al., 1991; Hiramatsu
et al., 1993; Lee et al., 1991), and cerebral damage (Lee et al., 1991;
Rami and Krieglstein, 1993). In addition, excitotoxic calpain
activation can induce calcium overload via inhibitory cleavage
of plasma membrane NCX3 (see Section 2.1.2 on NCX), and
inhibition of calpain or replacing endogenous NCX3 with the non-
degradable NCX2 prevents NMDAR-mediated calcium overload
and neuronal death (Bano et al., 2005). This positive-feedback
mechanism may partially explain how a small calcium transient
through the NMDAR can trigger a subsequent calcium overload
(Randall and Thayer, 1992; Tymianski et al., 1993a). Consistent
with the role of the GluN2B subunit in excitotoxicity (see Section
2.2.2), NMDAR-mediated calpain activation is blocked by a
selective antagonist of the GluN2BR, but not by an antagonist
that preferentially inhibits the GluN2AR (DeRidder et al., 2006;
Gascon et al., 2008; Zhou and Baudry, 2006). Consistent with the
theories that calpain acts downstream of the NMDAR and that the
targeting of downstream mechanisms may offer a wider window
of therapeutic opportunity, the calpain inhibitor MDL-28170
protected neurons against NMDAR-mediated excitotoxicity when
administered 1 h after receptor activation (Brorson et al., 1995). In
comparison, the NMDAR antagonist AP5, while equally neuropro-
tective when applied prior to NMDAR stimulation, had no effect
when applied 1 h after NMDAR stimulation (Brorson et al., 1995).
Like other treatments designed to target death-signaling cascades
downstream of the NMDAR, calpain inhibition has no effect on
NMDAR channel function (Brorson et al., 1995) and should have no
effect on non-calpain-dependent NMDAR signaling cascades and
functions. However, a number of calpain functions are required for
normal cellular function, and nonspeciﬁc inhibition of all calpain
activity can have adverse effects. This is an especially important
consideration, as calpain is ubiquitously expressed in almost all
animal cells. The identiﬁcation of the speciﬁc downstream
neuronal substrates of calpain that contribute to excitotoxicitycould lead to the development of stroke treatments with an
improved safety proﬁle compared to that of direct calpain
inhibition. Because many proteins are cellular targets for calpain
cleavage, it is expected that the diverse and widespread cleavage of
essential cellular proteins could result in multifactorial damage.
However, recent studies suggest that the calpain-mediated
cleavage of several distinct targets and their downstream signaling
pathways are especially neurotoxic (see Sections 4.3.1 and 4.3.2).
4.3.1. p25–cdk5 death-signaling
The 35-kDa regulatory activator (p35) of cdk5 is a brain-speciﬁc
calpain-substrate (Lew et al., 1994; Tsai et al., 1994), and both p35
and cdk5 are important signaling proteins required for maintain-
ing brain development and survival (Chae et al., 1997; Nikolic et al.,
1996; Ohshima et al., 1996; Paglini et al., 1998). Stimulation of the
NMDAR in primary cortical neurons by glutamate triggers calcium-
dependent calpain-mediated proteolytic cleavage of p35 into a
smaller 25-kDa form (p25) (Lee et al., 2000; O’Hare et al., 2005),
which induces neuronal death, in part by aberrant activation and
target-redirection of cdk5 (Patrick et al., 1999) (Fig. 6). As a result,
in these neurons, the inhibition of calpain or cdk5 prevents p25-
mediated neuronal damage (Alvarez et al., 2001; Lee et al., 2000;
O’Hare et al., 2005). It should also be noted that neurons
undergoing certain forms of non-excitotoxic damage also require
calpain-mediated production of p25 (Kusakawa et al., 2000; Nath
et al., 2000), suggesting that calpain inhibitors possess therapeutic
potential beyond excitotoxic neuronal damage. Consistent with its
essential role in excitotoxicity, increased levels of p25 are found in
the brains of mice subjected to focal ischemic stroke (Lee et al.,
2000; Nath et al., 2000) and global cerebral ischemia (Garcia-
Bonilla et al., 2006; Wang et al., 2003; Wen et al., 2007) and in brain
specimens from patients with Alzheimer’s disease (Patrick et al.,
1999) and ischemic stroke (Mitsios et al., 2007). Importantly,
conditional overexpression of p25 in the forebrain of transgenic
mice triggers neurodegeneration (Cruz et al., 2003), and inhibition
of cdk5 or its downstream targets prevents neuronal damage
induced by p25 and cerebral ischemia (Kim et al., 2008; Rashidian
et al., 2009; Wang et al., 2003). Although many proteins are
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p25 has been shown to be induced by cdk5-mediated phosphory-
lation of the GluN2A subunit of the NMDAR (Wang et al., 2003),
phosphorylation and inhibition of the transcription factor myocyte
enhancer factor 2 (Rashidian et al., 2009; Smith et al., 2006),
phosphorylation and inhibition of the antioxidant enzyme Prx2
(Qu et al., 2007; Rashidian et al., 2009), inhibition of histone
deacetylase 1 (Kim et al., 2008), and phosphorylation and
inhibition of apurinic/apyrimidinic endonuclease (Huang et al.,
2010).
4.3.2. Calpain-mediated cleavage of the NMDAR and mGluR
Among the substrates that are cleaved by calpain following
NMDAR stimulation, it is interesting to note that the GluN1,
GluN2A, and GluN2B subunits of the NMDAR are also substrates for
calpain cleavage (Bi et al., 1998). Like the S-nitrosylation-
dependent inhibition of GluN2A by nitric oxide that was described
earlier in this review (Takahashi et al., 2007), NMDAR stimulation
induces calpain-mediated cleavage of GluN2A-B, which results in
the depression of the NMDAR channel expression and function
(Guttmann et al., 2002; Wu et al., 2005). Interestingly, the GluN1/
GluN2A-containing NMDAR appears to be resistant to calpain
cleavage in hippocampal neurons (Bi et al., 1998; Simpkins et al.,
2003), despite being an active substrate when it is expressed in a
cell line (Guttmann et al., 2002). This resistance to calpain cleavage
in neurons appears to be due to the GluN2A–PSD95 interaction, as
calpain vulnerability can be alleviated by PSD95 overexpression in
a cell line and reinstated by disrupting the GluN2A–PSD95
interaction genetically or pharmacologically (Dong et al., 2004).
In contrast, calpain-mediated cleavage of GluN2B occurs in
neurons following only a brief exposure to NMDAR-mediated
excitotoxicity in vitro. More recently, a study demonstrated that
after prolonged in vitro NMDAR stimulation for 4 h as opposed to
the 30 min stimulation used in previous experiments, or after focal
ischemic stroke in vivo, both GluN2A and GluN2B are truncated by
calpain in neurons (Gascon et al., 2008). The observed lack of
PSD95-mediated resistance to calpain cleavage can be explained
by the ﬁnding that PSD95 itself was also lost to calpain cleavage
(Gascon et al., 2008) under these conditions. Interestingly, the
truncated NMDAR subunits can remain stable for some time post-
excitotoxicity (up to 48 h post ischemia) (Gascon et al., 2008;
Simpkins et al., 2003), but as their cytoplasmic tails, which are
critical for functional output, have been truncated (see Sections
2.2.2 and 4.1), these subunits are expected to have limited or
altered signaling output.
In addition to ionotropic glutamate receptors like the NMDAR,
calpain also directly cleaves the metabotropic glutamate receptor-
1 (mGluR1) following excitotoxic injury (Xu et al., 2007) (Fig. 6).
Importantly, this post-translational modiﬁcation of mGluR1
transforms it from a pro-survival receptor into a pro-death
receptor. Native mGluR1 forms a pro-survival complex with
Homer and long form of phosphoinositide 3 kinase enhancer (PIKE-
L) upon agonist-stimulation, and this multimeric mGluR1–Homer–
PIKE-L interaction is required for mGluR1-dependent activation of
the well-known pro-survival protein PI3K (see Section 3.1) and
neuroprotection against apoptotic cell death induced by staur-
osporine (Rong et al., 2003). Upon activation of the NMDAR,
however, calpain cleaves the cytoplasmic tail of mGluR1 at serine-
936, and this post-translational modiﬁcation reduces mGluR1-
mediated calcium release from internal stores, cationic current
from GIRK1, GIRK2, and TRPC1, and induction of PIK3 activity, as
measured by the level of Akt phosphorylation (Xu et al., 2007). In
addition, this modiﬁcation transforms the pro-survival effect of
mGluR1 stimulation into a pro-death effect (Xu et al., 2007). Based
on the amino acid sequence of the calpain cleavage site of mGluR1,
the interference peptide Tat-mGluR1 was developed to selectivelyblock this post-translational modiﬁcation. Like Tat-NR2B9c (see
Section 4.2.2), the Tat sequence rendered the peptide membrane-
permeable. Tat-mGluR1 prevents calpain-mediated mGluR1 trun-
cation in a dose-dependent manner and rescues mGluR1-mediated
pro-survival PI3K signaling. Notably, Tat-mGluR1 selectively
inhibits calpain-mediated cleavage of mGluR1 at low concentra-
tions (1–2 mM), but at marginally higher concentrations (4–8 mM),
Tat-mGluR1 becomes non-selective and inhibits calpain-mediated
cleavage of spectrin and possibly other proteins. Consistent with
the role of mGluR1 in excitotoxic neuronal death, Tat-mGluR1
prevents excitotoxic neuronal death in vitro and in vivo (Xu et al.,
2007). Importantly, the partial selectivity of Tat-mGluR1 for
inhibition of the calpain-mediated cleavage of mGluR1 but not
other calpain-mediated cleavages suggests that interference
peptides can be designed to be more speciﬁc than conventional
pharmacological calpain inhibitors.
4.3.3. STEP on death and survival
Another calpain target that mediates excitotoxicity is the brain-
speciﬁc death-signaling protein striatal-enriched protein tyrosine
phosphatase (STEP) (Fig. 6). Excitotoxicity induced by glutamate
triggers the activation of the two alternatively spliced variants of
STEP, STEP61 and STEP46, resulting in the dephosphorylation of
the key neuronal survival signaling proteins ERK and CREB (Paul
et al., 2003). Excitotoxic activation of the STEP splice variants, via
dephosphorylation of their kinase-interacting domains, which
bind to ERK and other substrates, requires activation of the
NMDAR, but not other glutamate receptors, and requires calcium
inﬂux from the NMDAR, but not other sources of calcium (Paul
et al., 2003). Importantly, synaptic NMDAR stimulation leads to
STEP61 ubiquitination and degradation, prolonging the ERK
activation that is needed for neuronal survival (Xu et al., 2009).
In contrast, extrasynaptic/GluN2B NMDAR stimulation triggers
calpain-mediated cleavage of STEP61 into STEP33, resulting in a
lack of p38 dephosphorylation (Mesﬁn et al., 2012; Xu et al., 2009).
Activated p38 (see Section 4.4.1) is thought to contribute to
extrasynaptic NMDAR-mediated excitotoxicity. Future studies are
needed to determine the mechanisms by which decreased levels of
STEP61, produced as a result of ubiquitination/degradation or
calpain-mediated cleavage, selectively lead to ERK stimulation
versus p38 activation, respectively. Importantly, the interference
peptide Tat-STEP, whose sequence resembles the calpain-cleavage
site of STEP61 and is rendered membrane permeable by the Tat
sequence, is protective against excitotoxic and ischemic neuronal
injury (Xu et al., 2009).
4.4. Transcription-dependent NMDAR death signaling
One of the hallmarks of ischemic neuronal death is the delayed
progression from the initial ischemic event to the resulting
neuronal death. As the long-term memory of many cellular events
involves transcriptional consequences, transcription is expected to
be required for neurons to ‘‘remember’’ that they were previously
ischemic and that they were programmed to undergo death at a
later time point. Several lines of evidence have demonstrated that
ischemic neuronal death is a transcription-dependent process that
requires the expression of death-signaling genes, as well as the
repression of survival-promoting genes (Dick and Bading, 2010;
Wahl et al., 2009; Zhang et al., 2007). Thus, targeting the
transcription factors that are responsible for neuronal death
may be a therapeutically favorable strategy, as it prevents the up-
regulation of many death-signaling genes and the down-regulation
of many survival-promoting genes at the latest converging points.
This strategy would allow for the widest therapeutic window for
effective drug administration without the need to target individual
genes for up-regulation or down-regulation. Among the signaling
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activated protein kinase (MAPK) family. Excluding ERK (also
known as classical MAPK), which is largely pro-survival and
participates in CREB activation (see Section 3.2), MAPK family
members, including p38 and c-Jun N-terminal kinase (JNK), are
stress-signaling proteins that translate cellular stress into tran-
scription-dependent responses (Derijard et al., 1994; Galcheva-
Gargova et al., 1994; Gupta et al., 1996; Han et al., 1994; Kyriakis
et al., 1994; Lee et al., 1994; Raingeaud et al., 1995; Rouse et al.,
1994). Thus, cellular stress is often accompanied by a decrease in
the phosphorylative activation of ERK, and apoptosis can be
prevented by ERK stimulation (Xia et al., 1995). In contrast,
apoptosis is often dependent on p38 and JNK activation and can be
ameliorated by inhibition of either of these kinases (Graves et al.,
1996; Verheij et al., 1996; Xia et al., 1995). A recent non-biased
screening assay identiﬁed sterol response element binding protein
1 (SREBP1), which is best known for its fundamental role in lipid
metabolism (Brown and Goldstein, 1997; Goldstein et al., 2006), as
a critical transcription factor for excitotoxicity and ischemic stroke
injury (Taghibiglou et al., 2009). Given the pivotal role of lipids in
neuronal death and survival (see Section 3.1), the novel excitotoxic
role of this transcription factor warrants future research.
4.4.1. From GluN2B-PSD95–nNOS to p38
The death-signaling MAPK p38 is a well-characterized contrib-
utor to NMDAR-mediated excitotoxicity, and recent studies report
that it is involved in death signaling downstream of the GluN2B–
PSD95–nNOS pathway (see Section 4.2). p38, also known as MAPK-
activated protein kinase-2 reactivating kinase (RK) or cytokine-
suppressive anti-inﬂammatory drug (CSAID)-binding protein
(CSBP), is activated by phosphorylation in response to endotoxin
and cellular stress (Graves et al., 1996; Han et al., 1994; Lee et al.,
1994; Raingeaud et al., 1995; Rouse et al., 1994). Excitotoxic
stimulation of the NMDAR triggers p38 activation (Cao et al., 2004,
2005; Kawasaki et al., 1997), and this activation requires inﬂux of
calcium through the NMDAR, but not concomitant calcium inﬂux
through voltage-gated calcium channels (Kawasaki et al., 1997).
Selective inhibition of p38 with the inhibitors SB203580 and
SB239063 prevents excitotoxic and anoxic neuronal death in vitro
(Barone et al., 2001b; Cao et al., 2004, 2005; Kawasaki et al., 1997;
Legos et al., 2002), and oral and intravenous prophylactic
administration of SB239063 and SB202190 protects the rat brain
against focal ischemic stroke damage in vivo (Barone et al.,
2001a,b; Soriano et al., 2008). Interestingly, recent studies suggest
that NMDAR-mediated p38 activation requires an intact GluN2B–
PSD95–nNOS interaction. Selective disruption of either the
GluN2B–PSD95 interaction or the PSD95–nNOS interaction via a
variety of interference peptides or protein fragments prevents
NMDAR-mediated p38 activation and attenuates neuronal death
(Cao et al., 2005; Soriano et al., 2008), whereas disruption of other
PSD95 binding proteins has no effect (Cao et al., 2005). Likewise,
glutamate-mediated p38 activation and neuronal death can be
attenuated by direct nNOS inhibition and exacerbated by nNOS
stimulation (Cao et al., 2005; Soriano et al., 2008). In addition, the
direct application of nitric oxide donors activates p38 and induces
neuronal death, and because it bypasses the GluN2B–PSD95–nNOS
pathway, this exogenous nitric oxide-mediated effect is not
affected by interference peptides that target PSD95–protein
interactions (Cao et al., 2005). Notably, two recent studies have
identiﬁed Rho and NOS1AP (nitric oxide synthase 1 adaptor
protein or CAPON (carboxyl-terminal PDZ ligand of nNOS))
signaling pathways in NMDAR/nitric oxide-mediated p38 activa-
tion (Li et al., 2013; Semenova et al., 2007). The relative
contribution by each pathway to p38 activation and whether
these two pathways interact or act independently of each other
remains unresolved. Thus, the evidence indicates that p38 actsdownstream of the GluN2B–PSD95–nNOS pathway in excitotoxi-
city. However, p38 is likely not the only death signaling molecule
downstream of this pathway. Glutamate-mediated p38 activation
peaks around 5 min post-treatment in cultured neurons, and it is
greatly reduced by 30 min and completely abolished by 60 min
post-treatment (Cao et al., 2004, 2005; Semenova et al., 2007). As a
result, SB203580 protects neurons against excitotoxicity when
applied 30 min before excitotoxic glutamate treatment, but not
when applied 30 min afterwards (Cao et al., 2005). In contrast,
although pretreatment with Tat-NR2B9c prevents glutamate-
mediated p38 activation and neuronal death, its therapeutic
efﬁcacy against neuronal death remains evident when it is applied
up to 60 min post-excitotoxic treatment (Aarts et al., 2002), a time
point when p38 is no longer active (Cao et al., 2004, 2005;
Semenova et al., 2007). This short therapeutic window would
render p38 inhibitors impractical as clinical stroke treatments. The
wider time window for effective administration of Tat-NR2B9c
suggests that p38 is not likely to be the only death signal
downstream of the GluN2B–PSD95–nNOS pathway.
4.4.2. JNK and the development of Tat-JBD20
The stress-associated MAPK JNK, also known as stress-activated
protein kinase (SAPK), is a primary target of excitotoxic neuronal
death. These kinases are notorious for their role in the death of
different cell types and can be activated via phosphorylation by a
variety of factors, including many non-excitotoxic apoptotic
factors, such as cellular stress and tumor necrosis factor (Derijard
et al., 1994; Galcheva-Gargova et al., 1994; Graves et al., 1996;
Kyriakis et al., 1994; Matsuda et al., 1995; Verheij et al., 1996).
There are three major subtypes of JNK, each with several sub-
isoforms that are generated by alternative mRNA splicing (Gupta
et al., 1996; Kuan et al., 1999; Martin et al., 1996). JNK1 and JNK2
are ubiquitously expressed and have been shown to be critical for
functional apoptosis during development (Kuan et al., 1999;
Martin et al., 1996). In contrast, JNK3 is largely expressed in the
nervous system (Kuan et al., 1999; Martin et al., 1996) and has
been directly implicated in excitotoxic neuronal death in vivo, as
JNK3-knockout mice are resistant to excitotoxic neuronal injury
(Yang et al., 1997). Because JNK activation is inhibited by binding of
the JNK-binding domain (JBD) of the JNK-interacting protein (JIP)
at the critical amino-acid-residues R156, R157, L160, and L162
(Barr et al., 2002; Bonny et al., 2001), overexpression of either full-
length JIP or the JBD fragment prevents JNK activity and
phosphorylation of its downstream substrates c-Jun and Elk-1
(Borsello et al., 2003). As such, JNK activity can be effectively
inhibited by Tat-JBD20 (also known as JNK inhibitor 1 (JNKI-1)),
whose sequence represents the JBD (amino acid residues 143–163
of JIP-1) fused to the membrane-permeability domain of the HIV1
Tat protein (Barr et al., 2002; Bonny et al., 2001; Borsello et al.,
2003). Although Tat-JBD20 inhibits JNK activity, this interference
peptide does not inhibit the phosphorylative activation of JNK
itself (Borsello et al., 2003). Due to sequence similarity with the JBD
of JIP-1, inhibitory effects on JNK activity can also be achieved with
peptides resembling the JBDs of JIP-2 and JIP-3 (Barr et al., 2002). In
addition, when this interference peptide is synthesized with D
amino acids, resulting in the peptide D-JNKI-1, it is resistant to
intracellular peptide degradation and therefore more potent than
the original L-JNKI-1 peptide that was synthesized with L amino
acids (Bonny et al., 2001; Borsello et al., 2003). This ﬁnding raises
the possibility that the bioavailability of other interference
peptides designed to inhibit NMDAR excitotoxicity or other
biological pathways may also be enhanced using D amino acids.
It is worth noting that the selectivity of JBD20 has been extensively
tested against a wide range of protein kinases, and the peptide
fragment potently inhibits JNK activity at 2.5–25 mM, but it has no
effect on the activity of ERK-2, p38, PKC, P34, CaMK, and PKA at
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other protein kinases that lack a small molecule-based drug
inhibitor, the large margin of selectivity offered by this peptide
suggests that the use of interference peptides is an important area
of research for future drug design and development.
Like Tat-NR2B9c, D-JNKI-1 is one of the earliest NMDAR-based
Tat-linked peptides to target death-signaling proteins downstream
of the surface receptor, and it has been shown in multiple studies
to be effective against stroke, even when administered several
hours after the ischemic event. JNK is activated as early as 10 min
post-excitotoxic NMDAR stimulation, and continues to be activat-
ed for at least 1 h (Borsello et al., 2003; Kawasaki et al., 1997). In
mice subjected to 30 min of transient focal ischemic stroke, JNK is
activated as early as 1 h post-ictus, and it remains activated up to
24 h post-ischemia (Borsello et al., 2003). Pretreatment with D-
JNKI-1 protected cortical neuronal cultures against excitotoxic
neuronal death in vitro and reduced ischemic neuronal death in
rats/mice subjected to focal ischemic stroke in vivo (Borsello et al.,
2003; Centeno et al., 2007; Esneault et al., 2008; Hirt et al., 2004).
Impressively, D-JNKI-1 has been shown to be effective against
stroke damage whether the drug is administered before stroke or
3–12 h after the initial ischemic event (Borsello et al., 2003). In
addition, the observed improvements in neurological outcome in
animals treated with D-JNKI-1 parallel a reduction of cerebral
infarction and are evident from 6 h up to 2 weeks post-ischemia
(Borsello et al., 2003). This wide time window for effective drug
administration supports the theory that inhibition of death-
signaling proteins downstream of the NMDAR can confer a wider
window of therapeutic opportunity than conventional treatments
that terminate NMDAR excitotoxicity at the receptor level. It
should also be noted that this window of opportunity is dependent
on the stroke model studied. In young P14 rats subjected to
permanent focal ischemia, D-JNKI-1 is neuroprotective when
infused before ischemia and at 3, 6, and 12 h post-ischemia
(Borsello et al., 2003). In contrast, in adult mice subjected to
transient 30 min focal ischemia, D-JNKI-1 is only effective when
administered before ischemia and at 3–6 h post-ischemia, but not
when administered 12 h post-ischemia (Borsello et al., 2003). In
addition, in adult rats subjected to permanent focal ischemia, D-
JNKI-1 is neuroprotective when administered 3 h but not 6 h post-
ischemia (Hirt et al., 2004).
4.4.3. New role of SREBP1 in neuronal death
SREBP1 (also known as adipocyte determination and differen-
tiation-dependent factor 1 (ADD1)), the principal transcription
factor for genes related to lipid metabolism (see review (Brown and
Goldstein, 1997; Goldstein et al., 2006)), was recently identiﬁed as
a death-signaling protein involved in NMDAR-mediated excito-
toxicity (Taghibiglou et al., 2009). NMDAR stimulation triggers
calcium-dependent and calpain-dependent proteolysis of protein
encoded by insulin-induced gene 1 (insig1), the inhibitory protein
that retains the inactive SREBP1 and SREBP cleavage-activating
protein (SCAP) complex in the endoplasmic reticulum (Gong et al.,
2006; Yang et al., 2000), allowing for the proteolytic activation of
SREBP1 and its subsequent translocation into the nucleus
(Taghibiglou et al., 2009). Consistent with the subunit speciﬁcity
of NMDAR in death signaling (see Section 2.2.2), excitotoxic
stimulation of SREBP1 is blocked by the GluN2BR antagonist but
not by the GluN2AR antagonist. Consistent with the role of nuclear
SREBP1 in excitotoxicity, the degree of nuclear translocation of
SREBP1 parallels the induction of neuronal death. Importantly,
genetic knockdown of SREBP1 or inhibition of SREBP1 activation
using the interference peptide Tat-INDIP (insig1-derived interfer-
ence peptide: GEPHKFKREW), whose sequence ﬂanks the lysine-
156 and 158 ubiquitination sites of insig1 that are required for
proteolysis (Gong et al., 2006) and is rendered membranepermeable with the membrane permeability sequence of the
HIV1 Tat protein, attenuates NMDAR-mediated excitotoxic neuro-
nal injury in vitro and ischemic stroke damage in vivo (Taghibiglou
et al., 2009).
5. Perspectives
Research into excitotoxicity was initially based upon food
safety concerns related to the use of monosodium glutamate, but
this process was quickly revealed as the principle mechanism
underlying neurodegeneration following cerebral ischemia and
many other neurodegenerative diseases, including brain trauma,
Huntington’s disease, Alzheimer’s disease, and ALS. Many ques-
tions about the molecular mechanisms that underlie excitotoxicity
remain unanswered. As scientists begin to understand the critical
role of the NMDAR and its calcium input in excitotoxicity, it
becomes important to determine the mechanisms by which
different subpopulations of the NMDAR and different sources of
calcium input can lead to vastly different cellular responses,
including opposing responses like neuronal death and survival.
Although evidence points to the cytoplasmic tail of the NMDAR as
the primary determinant of the receptor’s functional output, the
mechanisms by which death signaling proteins are speciﬁcally
recruited following cerebral ischemia and the mechanisms by
which death signaling proteins that do not bind to the NMDAR
cytoplasmic tail, such as calpain and JNK, are activated with
receptor subtype speciﬁcity and calcium source speciﬁcity remain
unclear. The emergence of molecular and cell biology has allowed
scientists to dissect the individual death-signaling proteins
involved in the progression from NMDAR stimulation to excito-
toxic neuronal death. Despite decades of research, new death-
signaling proteins downstream of the NMDAR are still emerging.
Studies have demonstrated that inhibiting these downstream
proteins is neuroprotective, but few studies have addressed how
these different death-signaling proteins work together, including
whether they work synergistically or in parallel to trigger
excitotoxicity. The downstream transcription factors and related
proteins, including p38, JNK, and SREBP1, are particularly
attractive therapeutic targets, because inhibition of these factors
is likely to affect the expression of large groups of excitotoxicity-
related genes without requiring treatment cocktails that individu-
ally target multiple genes.
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